US Pat. No. 11,110,053

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

REVEN PHARMACEUTICALS INC...


1. A therapeutic composition consisting of:an electro-activated solution with a stable negative oxidation-reduction potential in a range between 50 mV and 500 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the electro-activated solution consisting of:
0.5-10% magnesium sulfate hexahydrate;
5.0-20% ascorbic acid;
0.2-2.0% niacinamide;
0.2-2% pyridoxin HCl;
0.01-2.0% calcium D pantothenate;
0.1-1.0% thiamin HCl;
0.01-0.1% riboflavin;
0.001-0.1% cyanocobalamin;
0.5-10% sodium bicarbonate; 0.8-1% sodium chloride; and electrochemically activated water.

US Pat. No. 11,110,054

READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE

SLAYBACK PHARMA LLC, Pri...


1. A stable ready-to-use injectable pharmaceutical composition for reversing the effects of non-depolarizing neuromuscular blocking agents in a patient in need thereof, comprising (i) about 1 mg/mL of neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof, (ii) about 0.2 mg/mL of glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof, (iii) a pharmaceutically acceptable liquid vehicle, (iv) a tonicity modifier; and (v) a pH adjusting agent; wherein the level of Glycopyrrolate Impurity C in the composition is less than 1% when stored at 40° C. and 75% relative humidity for 3 months;wherein the tonicity modifier is sodium chloride; and
wherein the pH adjusting agent is sodium hydroxide, hydrochloric acid or a mixture thereof.

US Pat. No. 11,114,698

METHOD OF PREPARING POUCH TYPE SECONDARY BATTERY

LG Chem, Ltd., Seoul (KR...


1. A method of preparing a pouch secondary battery, the method comprising:accommodating an electrode assembly in an inner space of a pouch case to form a pouch preliminary secondary battery;
disposing a metallic ultrasonic member by being closely attached to both surfaces of the pouch type preliminary secondary battery;
injecting a composition for a gel polymer electrolyte into the pouch preliminary secondary battery;
applying ultrasonic vibration to the pouch preliminary secondary battery while pressurizing the pouch preliminary secondary battery using the metallic ultrasonic member;
performing formation of the pouch preliminary secondary battery;
curing the composition for a gel polymer electrolyte; and
degassing,
wherein the metallic ultrasonic member is maintained at a temperature of 30° C. to 80° C., and
the pressurizing of the pouch preliminary secondary battery is performed while applying a pressure of 0.1 kgf/cm2 to 3,000 kgf/cm2 per area of the pouch preliminary secondary battery.

US Pat. No. 11,110,312

MEDICATION DISPOSAL APPARATUS AND METHODS OF MANUFACTURE AND USE

Surgical Device Innovatio...


1. A medication disposal apparatus comprising:a collection chamber operable to receive a medication having an active agent;
a first converter housed in the collection chamber, the first converter operable to (i) receive the medication from the collection chamber, and (ii) convert the medication into a plurality of particles;
a reservoir fastened to the collection chamber; and
a second converter housed in the reservoir, the second converter operable to (i) receive the plurality of particles from the first converter, and (ii) deactivate the active agent.

US Pat. No. 11,111,340

METHOD FOR PREPARING BIOCOMPATIBLE POLY-?-GLUTAMIC ACID HYDROGEL BY USING ULTRAVIOLET RAYS

KOOKMIN UNIVERSITY INDUST...


1. A method of preparing a biocompatible poly-?-glutamic acid hydrogel comprising:dissolving poly-?-glutamic acid in a solvent (Step 1);
adding and dissolving N,N,N-trimethyl-3-[(2-methylacryloyl)amino]propane-1-aminium to solution of the poly-?-glutamic acid of the Step 1 (Step 2); and
irradiating the solution of the Step 2 with ultraviolet rays (Step 3),
wherein the N,N,N-trimethyl-3-[(2-methylacryloyl)amino]propane-1-aminium in the Step 2 is added at a molecular ratio of 1:1 with respect to molecule number of glutamic acid, which is a poly-?-glutamic acid monomer.

US Pat. No. 11,110,056

NASAL HYGIENE METHOD AND COMPOSITION


1. A system for rinsing a human nasal passage, the system comprising:a mixture comprised of water, chlorine dioxide, unsaturated fatty acid, olfactory stimulant, fixative compound, and inorganic salt; 0.001% to 1% by weight of cannabidiol oil; and an apparatus for dispensing 0.3 to 3 milliliters of the mixture into a nasal passage as a mist.

US Pat. No. 11,111,341

CLICK CHEMISTRY FOR SEALANTS AND ADHESIVES

Chem Link, Inc., Schoolc...


1. A method for producing a curable composition, comprising:reacting a functionalized polymer bearing a first functional group with a functionalized silane bearing a second functional group in the presence of a metal catalyst,
wherein the first functional group is selected from a group consisting of an azide and an alkyne;
wherein the second functional group is different from the first functional group and selected from a group consisting of an azide and an alkyne; and
wherein the result is a silyl-terminated polymer having a first silane group and a second silane group, the first silane group linked to the functionalized polymer via a first triazole moiety, and the second silane group linked to the functionalized polymer via a second triazole moiety;
wherein the metal catalyst promotes cross-linking of the first silane group and the second silane group in the presence of atmospheric moisture.

US Pat. No. 11,110,057

MICRO PARTICLES FOR ORAL DELIVERY IN ANIMALS

KEMIN INDUSTRIES, INC., ...


1. Microparticles for the controlled release of one or more physiologically or pharmacologically active substances, comprising:a core comprising one or more active substances, said one or more active substances being selected from the group consisting of lysine, choline, and methionine, said one or more active substances being intimately mixed with one or more carboxylic acids and/or their salts, said one or more carboxylic acids being selected from the group consisting of lauric, palmitic, stearic, oleic, arachidic, benzoic, adipic, and sebacic;
wherein the core exhibits controlled release of the one or more active substances such that less than 30% of the active substances are released within 24 hours; and
a coating on the core comprising a mixture of hydrogenated fatty acid glycerides, and further providing that said hydrogenated fatty glycerides comprise a C-16 fatty acid triglyceride content of between 40 and 70% and a C-18 fatty acid triglyceride content of between 30 and 50% of the total fatty acid content, wherein the amount of the coating is between 10 and 60% of the final weight of the microparticles.

US Pat. No. 11,110,058

PERIODONTIC TREATMENT AND METHOD


1. A method of root conditioning a root surface of a periodontitis-affected tooth of a subject in which the root surface is within a periodontal pocket, comprising:chemically debriding the root surface by applying a gel solution including a clinically effective amount of a peroxide and a clinically effective amount of tetracycline directly to the root surface with a manual dental instrument including a blade having a working edge with a surface roughness of 1 to 5 microns to chemically anesthetize the root surface; and
mechanically debriding the root surface, while performing the step of chemically debriding, by manually root planing the root surface with the dental instrument such that the peroxide and the tetracycline chemically anesthetize the root surface while the mechanical debridement step is performed, the root planing including contacting the root surface that includes the gel solution directly with the working edge of the blade to curettage the root surface to form a root surface roughness of 1 to 5 microns.

US Pat. No. 11,110,059

LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULFONAMIDES

AMMTEK, Paris (FR)


1. A liquid pharmaceutical formulation comprising between 0.5 and 7 mg/mL of micronized particles of glibenclamide, between 4.5 and 5.5 mg/mL of hydroxyethylcellulose, between 4.5 and 5.5 mg/mL of xanthan gum, a buffer system maintaining the pH of said formulation between 4.5 and 5.5, and between 4.5 and 5.5 mg/mL of sodium benzoate, wherein said formulation has osmolality below 400 mOsm/L, wherein the buffer system comprises lactic acid and between 6.75 and 8.25 mg/mL sodium citrate, wherein at least 90% of the micronized particles have a size less than 30 m, and wherein said formulation lacks a sugar-based sweetener.
US Pat. No. 11,110,060

COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS

Arizona Board of Regents ...


1. A composition, comprising: suramin nanoparticles or microparticles and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is selected from the group consisting of a) trehalose and b) a mixture of dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphoethanolamine-poly(ethylene glycol) (DPPE-PEG).
US Pat. No. 11,109,548

APPLICATION OF HIGH FLAVONOID ELITE GERMPLASM ‘CSR6R6-777’ IN BREEDING FOR FUNCTIONAL APPLE

SHANDONG AGRICULTURAL UNI...


1. A method for breeding apple elite germplasm, comprising:(a) obtaining a hybrid F1 population by crossing a M. sieversii f. niedzwetzkyana red flesh apple as a parent plant with a Red Fuji white flesh apple,
(b) identifying the apple elite germplasm from the hybrid F1 population based on phenotypes and a genotype, wherein the apple elite germplasm is identified as apple Malus domestica germplasm CSR6R6-777, of which a representative sample was deposited with the China General Microbiological Culture Collection Center under accession number CGMCC NO. 12468.

US Pat. No. 11,110,061

MICROSPHERICAL SUSTAINED-RELEASE INJECTION CONTAINING ESCITALOPRAM AND METHOD FOR PREPARING SAME

KOREA RESEARCH INSTITUTE ...


1. A sustained release injectable composition, comprising biodegradable polymer microspheres comprising escitalopram,wherein the microspheres further comprise a pharmaceutically acceptable hydrophobic solidifying agent to uniformly distribute the escitalopram in the microspheres,
wherein the biodegradable polymer is selected from at least one of the group consisting of polylactide, polyglycolide, poly (lactide-co-glycolide), and poly (lactide-co-glycolide) glucose, and
wherein the pharmaceutically acceptable hydrophobic solidifying agent is selected from the group consisting of dipalmitoyl phosphoric acid, stearic acid, lithocholic acid, hydroxy naphthoic acid, and a mixture thereof.

US Pat. No. 11,111,346

METAL-COATED NON-SPHERICAL RESIN PARTICLES AND METHOD FOR PRODUCING SAME, ALIGNED FILM OF METAL-COATED NON-SPHERICAL RESIN PARTICLES AND METHOD FOR PRODUCING SAME, PARTICLES, AND METHOD FOR PRODUCING PARTICLE-ALIGNED FILM

SEKISUI KASEI CO., LTD., ...


1. Metal-coated non-spherical resin particles, in which 20% or more and less than 80% of the surface of non-spherical resin particles is coated with metal,wherein the sphere-equivalent volume average particle diameter of the non-spherical resin particles is 0.1 to 300 ?m
and wherein the non-spherical resin particles have an aspect ratio of 1.2 or more.

US Pat. No. 11,111,603

METHODS AND MATERIALS FOR MULTIPLEXED COLLECTIONS OF FUNCTIONAL LIGANDS

Base Pair Biotechnologies...


1. A method for generating and utilizing a nucleic acid array comprising:providing a substrate with a plurality of single-stranded nucleic acid labels located and attached at predetermined addresses on said substrate, said single-stranded nucleic acid labels comprising an identical hybridization sequence and having a spacing region between said hybridization sequence and said substrate;
performing a hybridization of a single-stranded nucleic acid ligand to each of said plurality of single-stranded nucleic acid labels, each of said single-stranded nucleic acid ligands being potential aptamers with a complementary region to said hybridization sequence and a target binding region which is identical for each of said single-stranded nucleic acid ligands hybridized to one of said single-stranded nucleic acid labels at one of said predetermined addresses, wherein the identity of said single-stranded nucleic acid ligand hybridized at each predetermined address is known and is previously correlated to binding at least one target molecule, each of said hybridizations of said single-stranded nucleic acid ligands and said single-stranded nucleic acid labels comprising a signal interacting pair producing a signal interaction;
incubating said substrate with a sample; and
performing a detection operation to detect potential changes in said signal interactions after said incubating correlated to said addresses;

wherein said potential changes indicate binding of said at least one of said known target molecules to at least one of said plurality of single-stranded nucleic acid ligands when said potential change occurs after adding said sample.
US Pat. No. 11,109,549

TOMATO VARIETY NUN 00279 TOP

NUNHEMS B.V., Nunhem (NL...


1. A plant, a plant part or a seed of tomato variety NUN 00279 TOP, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 43684.
US Pat. No. 11,110,062

PHARMACEUTICAL COMPOSITION

TAIHO PHARMACEUTICAL CO.,...


1. A pharmaceutical composition, comprising:A 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N -methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof;
hydroxypropyl-?-cyclodextrin; and
the composition includes peaks at 5 or more diffraction angles 2? (±0.2°) selected from the group consisting of 6.5, 7.8, 9.6, 12.4, 18.8, 21.2, 23.0, 24.5, and 26.0)(°) in powder X-ray structure diffraction.

US Pat. No. 11,109,550

SOYBEAN VARIETY 01073116

Monsanto Technology LLC, ...


1. A plant of soybean variety 01073116, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-126424.
US Pat. No. 11,110,063

STORAGE STABLE SINCALIDE FORMULATIONS

MAIA Pharmaceuticals, Inc...


1. A solid composition comprising:(i) from 2.5 to 10 mcg of sincalide;
(ii) from 1 to 4 mg of pentetic acid;
(iii) from 15 to 45 mg of arginine hydrochloride;
(iv) from 2 to 8 mg of L-methionine;
(v) from 7.5 to 30 mg of L-lysine hydrochloride;
(vi) from 0.02 to 1 mg of sodium metabisulfite; and
(vii) from 85 to 340 mg of mannitol,wherein the solid composition comprises a pH of about 6.5 to about 7.5 when reconstituted in a pharmaceutically acceptable diluent,
wherein the solid composition does not contain a phosphate buffer,
wherein the solid composition does not contain a surfactant, a solubilizer, polysorbate 20, or polysorbate 80,
wherein the solid composition is formulated to be reconstituted in a pharmaceutically acceptable diluent for a quantity sufficient to 2.5 to 10 mL, and
wherein the solid composition maintains total impurities less than 5% after 15 months of storage at 25° C., 60% relative humidity or after 3 months of storage at 40° C., 75% relative humidity and optionally wherein the solid composition also maintains a sincalide level of at least 90% after 15 months of storage at 25° C., 60% relative humidity when tested by high-performance liquid chromatography.


US Pat. No. 11,109,551

SOYBEAN VARIETY 01073253

Monsanto Technology LLC, ...


1. A plant of soybean variety 01073253, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-126507.
US Pat. No. 11,110,064

GEL FORMULATION FOR TREATING DIABETIC FOOT ULCER INFECTIONS

SRM INSTITUTE OF SCIENCE ...


1. A gel formulation for treating diabetic foot ulcer infections, said formulation comprising:antibiotic loaded aquasomes having a diameter in the range of 80 nm to 120 nm as measured by a zeta sizer instrument;
a gelling agent;
a preservative; and
a fluid medium,
wherein said antibiotic loaded aquasomes includes antibiotic loaded on a polyhydroxy oligomer coated calcium phosphate,
wherein said polyhydroxy oligomer is selected from the group consisting of lactose, trehalose, and cellobiose,
wherein said antibiotic loaded aquasomes include a calcium phosphate core having a particle diameter in the range of 45 nm to 55 nm as measured by a zeta sizer instrument, coated with polyhydroxy oligomer thereon followed by coating of an antibiotic on said aquasomes,
wherein said aquasomes are in an amount in the range of 15 wt % to 20 wt % of the total weight of said formulation; said gelling agent is in an amount in the range of 70 wt % to 90 wt % of the total weight of said formulation; said preservative is in an amount in the range of 0.05 wt % to 0.25 wt % of the total weight of said formulation; and said fluid medium is in an amount in the range of 1 wt % to 4 wt % of the total weight of said formulation,
wherein the pH of said gel formulation is in the range of 6.0 to 7.0, and
wherein the said the gel formulation is stable over the period of 6 months.

US Pat. No. 11,111,349

MOLDED FOAM

KYORAKU CO., LTD., Kyoto...


1. A blow molded foam molded from a foamed resin made of a polyethylene-based resin, the blow molded foam being an automobile duct configured to circulate cool or warm aft supplied from an air conditioning unit,wherein the blow molded foam has a MFR (190° C., g/10 min) of not less than 0.17 and not more than 0.40, and wherein a surface roughness Rmax of the blow molded foam is 200 ?m or less,
wherein the polyethylene-based resin has a MFR (190° C., g/10 min) of not less than 0.34 and not more than 1.0,
wherein the polyethylene-based resin consists of:a high-density polyethylene-based resin of between 50 parts by mass and 90 parts by mass, wherein the high-density polyethylene-based resin has a density 0.949 g/cm3, a MFR of 0.3 g/10 min, and
a low-density polyethylene-based resin of between 10 parts by mass and 50 parts by mass, wherein the low-density polyethylene-based resin has a density 0.919 g/cm3, a a MFR of 1.7 g/10 min.


US Pat. No. 11,110,065

SINTERED FERROUS AMINO ACID PARTICLES AND USE OF THE SAME AGAINST A VIRUS

PROFEAT BIOTECHNOLOGY CO....


1. A composition comprising sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate, the ferrous amino acid chelate including a ferrous ion and an amino acid, and the sintered ferrous amino acid particles having an average particle size ranging from 500 to 2600 nm and a weight average molecular weight ranging from 1,500 Dalton to 600,000 Dalton.
US Pat. No. 11,111,607

PROCESS FOR MAKING HIGH-STRENGTH POLYLACTIC ACID FILAMENT

DSM IP ASSETS B.V., Heer...


1. A process for making a polylactic acid (PLA) elongated object comprising the steps of:a) making a solution of PLA having an intrinsic viscosity (IV) measured in chloroform at 25° C. of at least 4 dL/g, in a solvent, wherein the solution has a concentration ccP of 5 to 50 mass% expressed as the mass of the PLA per total mass of the solution;
b) spinning the solution through a spinplate comprising at least 1 spinhole to form a fluid elongated object;
c) optionally applying a draw ratio DRfluid to the fluid elongated object;
d) contacting the fluid elongated object with a cooling medium having a temperature Tq of less than 0° C. to form a solvent-containing gel elongated object;
e) removing at least partly the solvent from the gel elongated object to form a solid elongated object; and
f) drawing the elongated object in at least one step before, during and/or after step e), while applying a draw ratio (DRsolid) of at least 2, to form a PLA elongated object.

US Pat. No. 11,114,709

BATTERY MODULE

PANASONIC INTELLECTUAL PR...


1. A battery module comprising:a battery stack including a plurality of stacked batteries and having a first surface and a second surface extending in a direction intersecting with the first surface;
a first heat radiator facing the first surface of the battery stack;
a first heat transfer component that is disposed between the first surface of the battery stack and the first heat radiator, and is in contact with the first heat radiator and the first surface to transfer heat from the battery stack to the first heat radiator; and
a second heat radiator facing the second surface of the battery stack, and is thermally connected to the second surface directly or through a second heat transfer component, the second heat radiator being attached to the first, heat radiator,
wherein a position of a center of the battery: stack projected on the first heat transfer component is located between a center of the first heat transfer component and the second heat radiator in a direction along the first surface.

US Pat. No. 11,110,066

IMPLANTABLE DEVICES FOR DELIVERY OF BIOACTIVE AGENTS

SORRENTO THERAPEUTICS, IN...


1. A fully implantable delivery device configured to deliver a bioactive agent to a subject, the device comprising:the bioactive agent;
a wall having a surface;
a plurality of nanostructures extending from the surface of the wall, at least a portion of the nanostructures having a cross-sectional dimension of greater than about 5 nanometers and less than about 500 nanometers, and a height of greater than about 5 nanometers to less than about 1 micrometer, and wherein at least a portion of the nanostructures have a center-to-center spacing of greater than about 50 nanometers to less than about 1 micrometer, and
a plurality of microstructures extending from the surface of the wall, at least a portion of the microstructures having a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, wherein the cross-sectional dimension of each nanostructure of the plurality of nanostructures is smaller than the cross-sectional dimension of each microstructure of the plurality of microstructures;
wherein the plurality of nanostructures and plurality of microstructures are arranged in a fractal dimension of greater than about 1; and
wherein the surface containing the plurality of nanostructures and plurality of microstructures has an average surface roughness, as determined by an arithmetical mean height of a surface area roughness parameter as defined by ISO 25178, between about 10 nanometers and about 200 nanometers.

US Pat. No. 11,111,351

FOAMING PARTICLE MOLDED BODY

JSP Corporation, Tokyo (...


1. An expanded beads molded article, which is obtained through in-mold molding of expanded thermoplastic elastomer beads, comprises voids among expanded beads, and has a density of 150 to 300 kg/m3 and a voidage of 10 to 70% by volume.
US Pat. No. 11,109,554

SOYBEAN CULTIVAR 83211737

M.S. Technologies, L.L.C....


1. A plant of soybean cultivar 83211737, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 202105001.
US Pat. No. 11,110,067

INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN

The Board of Regents of t...


1. A microcapsule consisting essentially of a core component comprising at least 5% by weight of an inhibitor of mammalian target of rapamycin (mTOR) which is rapamycin or a rapamycin analog, wherein said core component is microencapsulated and encased in a coating that includes a methyl methacrylate-methacrylic acid copolymer.
US Pat. No. 11,111,352

METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF

ExxonMobil Research and E...


1. A method for preparing an organosilica material, the method comprising:(a) providing a starting material mixture comprising at least one compound of Formula [(RO)2SiCH2]3 (Ia) and at least one compound of Formula [R?ROSi CH2]3 (Ib), wherein each R? independently represents an RO— group, an R group, or an (RO)3Si—CH2— group, at least one R? being (RO)3Si—CH2—; and R represents a C1-C4 alkyl group;
(b) adding the starting material mixture into an acidic or basic aqueous mixture wherein the weight ratio between Formula (Ia) and Formula (Ib) is about 1:1 to about 5:1 such that the resulting solution contains essentially no structure directing agent;
(c) curing the solution to produce a pre-product; and
(d) drying the pre-product to obtain the organosilica material which is a polymer comprising:

independent siloxane units of Formula [R1R2SiCH2]3 (I), wherein each R1 represents a hydroxyl group, a C1-C4 alkoxy group, or an oxygen atom bonded to a silicon atom of another siloxane unit and each R2 represents a hydroxyl group, a C1-C4 alkoxy group, a C1-C4 alkyl group, or an oxygen atom bonded to a silicon atom of another siloxane, wherein the organosilica material having a total surface area of about 50 m2/g to about 2500 m2/g and an average pore diameter greater than about 1.0 nm.
US Pat. No. 11,109,555

SOYBEAN CULTIVAR 132421850112

Benson Hill Seeds, Inc., ...


1. A plant or a seed of soybean cultivar 132421850112, wherein a representative sample of seed of said cultivar is deposited under NCMA No. 202101089.
US Pat. No. 11,110,068

COMPOSITIONS COMPRISING A DENDRIMER-RESVERATROL COMPLEX AND METHODS FOR MAKING AND USING THE SAME

Concordia University, Me...


1. A method of treating a skin condition or disorder, the method comprising topically administering to skin or mucous membrane of a subject in need thereof a therapeutically effective amount of a semi-solid composition comprising a dendrimer-resveratrol complex, wherein the concentration of dendrimer is less than 0.40 mM, wherein at least 50%, by weight, of the resveratrol associated with dendrimer permeates the skin in 20 minutes or less in a transdermal permeation study utilizing Franz Diffusion Cells and rat skin samples.
US Pat. No. 11,109,556

SOYBEAN CULTIVAR 2478752

Benson Hill Seeds, Inc., ...


1. A plant or a seed of soybean cultivar 2478752, wherein a representative sample of seed of said cultivar is deposited under NCMA No. 202104001.
US Pat. No. 11,110,069

COMPOSITION COMPRISING CANNABINOIDS FOR RELIEF OF PAIN

TWEED INC., Smiths Falls...


1. A composition for topical application comprising:at least one purified cannabinoid, wherein the purified cannabinoid is cannabidiol (CBD);
at least one anti-inflammatory agent in an amount ranging from between about 10 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and
at least one botanical extract, wherein the botanical extract is arnica.

US Pat. No. 11,111,354

SYSTEMS AND METHODS FOR PRODUCING AEROGEL MATERIALS

Aerogel Technologies, LLC...


1. A method of manufacturing an aerogel, comprising:freezing a solvent within a precursor gel material comprising the solvent; and
sublimating the solvent at about atmospheric pressure to produce the aerogel;
wherein:the solvent comprises tert-butanol,
the aerogel has at least one dimension greater than or equal to about 1 m,
the aerogel exhibits a compressive modulus greater than or equal to about 100 kPa,
the aerogel exhibits a compressive yield strength greater than or equal to about 20 kPa, and
the aerogel has at least one dimension having a length that is within about 20% of the length of a corresponding dimension of the precursor gel material of the aerogel immediately prior to the sublimating.


US Pat. No. 11,111,611

ELECTROSPUN PNIPAAM/PCL FIBER MATS FOR ALIGNED CELL SHEETS

Board of Regents, The Uni...


1. A fiber mat comprising poly(N-isopropylacrylamide) (PNIPAAm) and poly(caprolactone) (PCL), wherein PNIPAAm content is at least 90%.
US Pat. No. 11,109,557

SOYBEAN CULTIVAR 98110162

M.S. Technologies, L.L.C....


1. A plant of soybean cultivar 98110162, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 202012097.
US Pat. No. 11,110,070

PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS

The Trustees of Columbia ...


1. A method for preventing or delaying a stress-induced affective disorder or stress-induced psychopathology in a subject, the method consisting of administering, once or twice, an effective amount of a pharmaceutic composition consisting of ketamine to the subject, wherein the method consists of administering the pharmaceutic composition to the subject 1 week prior to the stressor.
US Pat. No. 11,111,355

ADDITION OF BIODEGRADABILITY LENDING ADDITIVES TO PLASTIC MATERIALS

BIOLOGIQ, INC., Idaho Fa...


1. A method for lending biodegradability to a plastic material that itself is not otherwise biodegradable, the method comprising:providing a plastic material that is not biodegradable on its own;
providing a starch-based polymeric material formed from a chemical reaction and/or alternation of starch and a plasticizer, wherein said starch-based polymeric material: (1) is substantially devoid of starch in native form; (2) has a crystallinity of less than about 20% and resists recrystallization; (3) has a water content of no more than about 2% by weight; and (4) when blended in a mixture with the plastic material that is not biodegradable on its own, the blend exhibits a lack of sea-island features within said blend;
providing at least one degradation additive that in combination with at least one of oxygen, ultraviolet light, or microbial action enables biodegradation of the plastic material that is not itself biodegradable; and
blending the starch-based polymeric material, the plastic material and the at least one degradation additive;
wherein at least 10% of the carbon atoms of the plastic material become carbon atoms of at least one of carbon dioxide or methane within about 1 year in simulated landfill conditions, simulated compost conditions or simulated marine conditions.

US Pat. No. 11,111,612

HIGH MELT FLOW FLUOROPOLYMER COMPOSITION

Arkema Inc., King of Pru...


1. A fluoropolymer composition comprising a fluoropolymer, wherein said fluoropolymer is a homopolymer of vinylidene fluoride or a copolymer having a random homogeneous distribution of monomers and at least 70 weight percent of vinylidene fluoride monomer units; and wherein said fluoropolymer has a melt viscosity of 0.01 to 0.4 kP, at 100 s?1 and 232° C., as measured by parallel plate rheology, and has a weight average molecular weight of from 15,000 to 140,000 Dalton as measured by GPC relative to polymethyl methacrylate (PMMA) narrow standards.
US Pat. No. 11,109,558

SOYBEAN CULTIVAR 91220032

M.S. Technologies, L.L.C....


1. A plant of soybean cultivar 91220032, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 202012059.
US Pat. No. 11,110,071

PETROLATUM-BASED PHMB COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSIS


1. A method of treating onychomycosis in a subject, the method comprising applying a petrolatum-based polyhexamethylene biguanide (PHMB) composition to the nail of a subject in need of treatment, wherein the petrolatum-based PHMB composition comprises greater than about 90% by weight petrolatum.
US Pat. No. 11,111,356

ATTRITION-RESISTANT SUPERABSORBENT POLYMER, METHOD FOR PREPARING THE SAME AND COMPOSITION FOR PREPARING THE SAME

LG Chem, Ltd.


1. An attrition-resistant superabsorbent polymer comprising:a superabsorbent polymer having a crosslinked surface;
water;
particles;
aluminum sulfate;
citric acid; and
propylene glycol,
wherein the particles have a BET specific surface area of 300 to 1500 m2/g and
a porosity of 50% or more,
wherein the water, the particles, the citric acid, and the propylene glycol are present in respective amounts of 2.5 to 7.5 parts, 0.001 to 2.0 parts, 0.001 to 5.0 parts and 0.01 to 5.0 parts based on 100 parts by weight of the superabsorbent polymer, and
wherein the attrition resistant superabsorbent polymer has a change in particle size before and after ball milling of ?5.8% to ?9.0%, wherein the ball milling was performed for 20 min at 300 rpm using 20 g of the attrition resistant superabsorbent polymer in the presence of 10 alumina balls, each alumina ball having 2.5 cm diameter.

US Pat. No. 11,114,715

ENCLOSURE ASSEMBLIES WITH IMPROVED ELECTROMAGNETIC COMPATIBILITY

FORD GLOBAL TECHNOLOGIES,...


1. A vehicle electrical module, comprising:a component;
an enclosure assembly housing the component,
wherein the enclosure assembly includes a polymer-based substrate and a metallic foil adapted to improve an electromagnetic compatibility of the polymer-based substrate; and
a compression limiter received within an opening of the enclosure assembly and adapted to establish a conductive path between the metallic foil and a different metallic component,
wherein a first portion of the metallic foil is located inwardly from an outer layer of the polymer-based substrate and a second portion of the metallic foil lines a surface of the outer layer that circumscribes the opening.

US Pat. No. 11,110,072

BROAD SPECTRUM PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF VARIOUS INFECTIONS AND DISEASES AND METHODS OF USE

Greyfer Innova Pharma, LL...


1. A method of treating a lice infection in a mammal having such lice infection in a specific area of skin and hair of the mammal, comprising:topically applying to the specific area of the skin and hair a therapeutically effective amount of a pharmacological composition to kill the lice and dislodge them from the mammal skin and hair, comprising:
a pharmaceutical carrier;
an active composition consisting of an amount of about 2% to 10% a mixture of sodium oxalate and oxalic acid;
wherein the pharmacological composition is safe and effective for the treatment of lice in the mammal.

US Pat. No. 11,111,357

USE OF MIXTURES OF MONOPEROXYCARBONATE PEROXIDES FOR THE CROSS-LINKING AND COMPOSITION OF CROSS-LINKABLE POLYMERS

ARKEMA FRANCE, Colombes ...


1. A crosslinkable composition comprising at least one ethylene-vinyl acetate (EVA) copolymer and a combination of peroxides, wherein the combination of peroxides comprises:(i) O,O-tert-butyl O-isopropyl monoperoxycarbonate or O,O-tert-amyl O-isopropyl monoperoxycarbonate; and
(ii) O,O-tert-butyl O-2-ethylhexyl monoperoxycarbonate or O,O-tert-amyl O-2-ethylhexyl monoperoxycarbonate,
in a mass ratio of 40%/60% to 60%/40% of peroxide (i)/peroxide (ii),
wherein the total amount of peroxide (i) and peroxide (ii) represents between 0.2% and 4% of the mass amount of the polymer present in the composition.

US Pat. No. 11,109,560

TOMATO VARIETY NUN 09247 TOF

NUNHEMS B.V., Nunhem (NL...


1. A plant, plant part, or seed of tomato variety NUN 09247 TOF, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 43642.
US Pat. No. 11,110,073

STORAGE STABLE AQUEOUS INJECTABLE SOLUTION COMPRISING DICLOFENAC

CADILA HEALTHCARE LIMITED...


1. An aqueous solution for parenteral administration comprising diclofenac sodium, polysorbate 80 and polyvinylpyrrolidone, wherein the solution has a pH between about 7 and about 10, and wherein the solution remains clear after 6 months of storage at 25° C.
US Pat. No. 11,109,561

TOMATO VARIETY NUN 09261 TOF

NUNHEMS B.V., Nunhem (NL...


1. A plant, plant part, or seed of tomato variety NUN 09261 TOF, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 43641.
US Pat. No. 11,110,074

METHODS OF IMPROVING THE PHARMACOKINETICS OF DOXEPIN

Currax Pharmaceuticals LL...


1. A method of treating insomnia, the method comprising:administering between about 0.5 mg and 7 mg doxepin to a patient in need thereof, wherein the doxepin is administered at least 3 hours after consuming a meal to provide faster onset of action.

US Pat. No. 11,111,359

METHOD FOR PRINTING LOW-DENSITY POLYMER STRUCTURES

UT-Battelle, LLC, Oak Ri...


1. A method of forming a low-density three-dimensional article, said method comprising:A) printing a low-density composition on a substrate via extrusion deposition to form at least one layer comprising the low-density composition, wherein the low-density composition is a thermoplastic comprising a polymer component (P) and a microsphere component (M) in a ratio by volume (P):(M);
B) selectively controlling a density of the low-density composition during printing A) by varying the ratio (P):(M) during extrusion deposition of the low-density composition to give the at least one layer on the substrate; and
C) repeating A) and B) to form additional layer(s).

US Pat. No. 11,111,360

RUBBER COMPOSITION COMPRISING AT LEAST ONE SILICA AS INORGANIC REINFORCING FILLER

COMPAGNIE GENERALE DES ET...


1. A rubber composition based on at least one elastomer, a reinforcing inorganic filler, an agent for coupling the elastomer to the reinforcing inorganic filler, and a crosslinking system, wherein the reinforcing inorganic filler comprises at least one silica S having:a CTAB specific surface area SCTAB within a range extending from 40 to 300 m2/g;
a difference between a BET specific surface area SBET and the CTAB specific surface area SCTAB of greater than or equal to 35 m2/g;
an aluminium content WAl within a range extending from 0.5 to 7.0% by weight relative to a weight of the silica S;
a width of the aggregate size distribution Ld, measured by centrifugal sedimentation, of greater than or equal to 1.5; and
a median aggregate diameter d50, measured by centrifugal sedimentation, such that for a given value of CTAB specific surface area SCTAB and a given aluminium content WAl, a magnitude A is defined by the following equation (I):A=[d50]+0.782×[SCTAB]?8.524×[WAl]??(I)

in which:[d50] is the numerical value of d50, expressed in nm;
[SCTAB] is the numerical value of SCTAB, expressed in m2/g;
[WAl] is the numerical value of WAl, expressed in % by weight relative to the weight of the silica S; and
the magnitude A satisfies the relationship (II):A?253??(II), and


wherein the content of reinforcing inorganic filler is within a range extending from 80 to 150 phr.

US Pat. No. 11,110,076

METHODS OF TREATING DISORDERS ASSOCIATED WITH GLYCOSYLATION DEFECTIVE PROTEINS

CASE WESTERN RESERVE UNIV...


1. A method of treating a glycosylation-defective protein associated disease or disorder in a subject in need thereof, the method comprising:administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor, wherein the SERCA inhibitor induces unconventional secretory pathway transport of aggregated glycosylation-defective protein from endoplasmic reticulum of cells of the subject.

US Pat. No. 11,111,361

ENERGY ABSORBING BLENDS

DESIGN BLUE LIMITED, Hov...


1. A molded article comprising an un-comminuted composite material which is elastic, exhibits a resistive load under deformation which increases with the rate of deformation, and comprises:i) a first polymer-based elastic material comprising a polymer selected from the group consisting of elastomeric polyurethanes and synthetic thermoplastic elastomers; and
ii) a second polymer-based material, comprising a polymer different from the polymer of i), which exhibits dilatancy in the absence of i) wherein ii) is entrapped in a solid matrix of i),
the composite material being un-foamed and,
the first material i) and second material ii) being in intimate admixture;

wherein the second material ii) forms from 5% to 80% by volume of the composite material.
US Pat. No. 11,110,077

APREMILAST PHARMACEUTICAL COMPOSITIONS

SARUDBHAVA FORMULATIONS P...


1. A topical pharmaceutical composition of apremilast, comprising:a. 1-5% w/w of apremilast or pharmaceutically acceptable salt thereof;
b. a first pharmaceutically acceptable carrier at a concentration range of 5-30% w/w; and
c. a pharmaceutically acceptable excipient;
wherein the first pharmaceutically acceptable carrier is selected from the group consisting of dimethyl sulfoxide, glycerol, propylene glycol, petrolatum, water, and a mixture thereof,
wherein the pH of the said composition is ranging from pH 3 to 8, and
wherein the said topical composition has the ratio of apremilast to carrier in the range of 1:100 to 100:1.

US Pat. No. 11,111,362

BREATHABLE FILMS WITH MICROBIAL BARRIER PROPERTIES

Becton, Dickinson and Com...


1. A film for a medical device or packaging formed from a blend comprising:a base polymeric formulation comprising polyethylene and poly(ethylene oxide), the polyethylene being present in the blend in an amount in the range of about 50 to less than 70% by weight and the poly(ethylene oxide) being present in the blend in an amount in the range of greater than 25 to about 50% by weight; and
an additive comprising a polyethylene-poly(ethylene oxide) amphiphilic graft copolymer (PE-g-PEO) being present in the blend in an amount in the range of about 0.01 to about 5.0% by weight, wherein a portion of the PEO of the amphiphilic graft copolymer (PE-g-PEO) comprises end groups directly bonded to a nitric oxide-releasing agent;
wherein the film is both breathable and a microbial barrier.

US Pat. No. 11,111,364

FLAME RETARDANT POLYMER COMPOSITE MATERIALS AND METHODS OF MAKING THE SAME

Case Western Reserve Univ...


1. A polymer composite material, comprising a blend of one or more thermoplastic polymers and one or more bio-based flame retardant additives, wherein the one or more thermoplastic polymers comprises polystyrene and the one or more bio-based flame retardant additives comprises gelatin, wherein the one or more bio-based flame retardant additives are present in an amount of 35 to 100 parts per 100 parts by weight of the one or more thermoplastic polymers, and wherein the gelatin is present from about 40 to about 100 parts per 100 parts by weight of the one or more thermoplastic polymers.
US Pat. No. 11,114,723

BATTERY ARRAY MOUNTING AND SUPPORTING BRACKETS

FORD GLOBAL TECHNOLOGIES,...


1. A battery pack, comprising:an enclosure assembly;
a component housed within the enclosure assembly;
a bracket adapted to connect to both a support structure of the component and the enclosure assembly,
wherein the support structure includes a pair of end plates and a pair of side plates;
a first fastener received through the bracket and into the enclosure assembly; and
a second fastener received through the bracket and into a portion of the support structure,
wherein a body of the bracket is Y-shaped and includes a pair of curved mounting arms, and further wherein the second fastener is received through a mounting tab of one of the curved mounting arms of the pair of curved mounting arms.

US Pat. No. 11,111,365

POLYOLEFIN STRUCTURE

Mitsubishi Gas Chemical C...


1. A polyolefin-based structure comprising 60 to 97% by mass of an unmodified polyolefin (A), 1 to 35% by mass of an acid-modified, polyolefin (B), and 2 to 35% by mass of a polyamide resin (C), wherein the polyamide resin (C) is dispersed in a layered form in the unmodified polyolefin (A) and the acid-modified polyolefin (B), and the polyamide resin (C) is a melt-kneaded product of 30 to 70% by mass of a polyamide (X) that contains a diamine unit containing 70 mol % or more of a m-xylylenediamine unit and a dicarboxylic acid unit containing an ?,?-linear aliphatic dicarboxylic acid unit and 30 to 70% by mass of an aliphatic polyamide (Y), provided that a total of the polyamide (X) and the polyamide (Y) is taken as 100% by mass, and a difference between a melting point Tmo of the polyamide (X) prior to melt kneading as observed by differential scanning calorimetry and a melting point Tm1 derived from the polyamide (X) in the polyamide resin (C), is from 0.1 to 2.5° C.
US Pat. No. 11,110,081

TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS

VELOXIS PHARMACEUTICALS, ...


1. A method of prophylaxis of organ rejection in a de novo kidney transplant patient comprising once daily orally administering to the patient an effective amount of tacrolimus in the form of one or more extended release compositions comprising tacrolimus, wherein (i) the initial dose of tacrolimus is 0.14 mg/kg/day, and (ii) the Tmax on day 1, when administered under fasting conditions, is between 4 hours and 24 hours.
US Pat. No. 11,111,366

POLYOLEFIN COMPOSITIONS WITH IMPROVED MECHANICAL AND BARRIER PROPERTIES

Universidade Federal do R...


1. A process for preparing a polymer composition, the process comprising:mixing a polyolefin, a polar polymer, and a crosslinking agent;
during the mixing, selectively crosslinking the polar polymer with the crosslinking agent in the presence of the polyolefin to generate a masterbatch polymer composition; and
mixing the masterbatch polymer composition with a second amount of polyolefin.

US Pat. No. 11,111,367

RESIN MOLDED BODY AND METHOD FOR PRODUCING RESIN MOLDED BODY

KYOCERA CORPORATION, Kyo...


1. A resin molded body, comprising:a polyolefin element formed of polyolefin, comprising a crystalline region and an amorphous region; and
a hydrophilic copolymer contained in at least part of a surface of the polyolefin element and in part of the amorphous region that is located below the surface,
the hydrophilic copolymer comprising a copolymer of 2-methacryloyloxyethyl phosphorylcholine of 45% or greater on a mole fraction basis, and at least one other monomer.

US Pat. No. 11,110,084

OPIOID FORMULATIONS

Camurus AB, Lund (SE)


1. A depot precursor formulation comprising:a) a lipid controlled release formulation comprising i) phosphatidylcholine and ii) glycerol dioleate, wherein the phosphatidylcholine is about 10 to about 25% by weight of the total weight of the depot precursor formulation, and the glycerol dioleate is about 15 to about 25% by weight of the total weight of the depot precursor formulation;
b) about 25 to about 32% by weight of N-methyl-2-pyrrolidone; and
c) about 25 to about 50% by weight of buprenorphine.

US Pat. No. 11,111,369

FOAMED POLYPROPYLENE COMPOSITION

BOREALIS AG, Vienna (AT)...


1. A polypropylene composition (C), comprising:a) a first heterophasic propylene copolymer (HECO1) having a comonomer content of the xylene soluble fraction (XCS) equal or above 40.0 mol %, said first heterophasic propylene copolymer comprising:i) a first matrix being a first propylene polymer (M1) and
ii) a first elastomeric propylene copolymer (E1) being dispersed in said first matrix,

b) a second heterophasic propylene copolymer (HECO2) having a comonomer content of the xylene soluble fraction (XCS) below 39.0 mol %, wherein the xylene soluble fraction (XCS) of the second heterophasic copolymer (HECO2) has an intrinsic viscosity (IV) above 3.5 dl/g, said second heterophasic propylene copolymer comprising:iii) a second matrix being a second propylene polymer (M2) and
iv) a second elastomeric propylene copolymer (E1) being dispersed in said second matrix,

c) an inorganic filler (F),
d) optionally a high density polyethylene (HDPE), and
e) optionally a plastomer (PL) being a copolymer of ethylene and a C4 to C8 ?-olefin.

US Pat. No. 11,110,085

CO-SPRAY DRYING OF CIPROFLOXACIN AND COLISTIN AND THE USES THEREOF

Purdue Research Foundatio...


1. A process for manufacturing a dry powder composition consisting of leucine, dual antibiotics of a polymycin and a quinolone, comprising the steps ofa. dissolving leucine, a polymyxin compound and a quinolone compound, or a pharmaceutically acceptable salts thereof, respectively, in an aqueous or an organic medium to prepare a solution;
b. adding one or more pharmaceutically acceptable excipients to said solution; and
c. spray-drying to afford said dry powder composition of dual antibiotics with an improved inhalable fraction of said antibiotics and an increased physical stability and aerosolization stability as compared with quinolone alone.

US Pat. No. 11,111,370

PROMOTED MEMBRANE FOR SINGLE-PLY ROOFING

STEPAN COMPANY, Northfie...


1. A promoted membrane, comprising:(a) an ethylene-propylene-diene rubber (EPDM); and
(b) incorporated within the rubber, 1 to 10 wt. %, based on the amount of promoted membrane, of an adhesion promoter, the adhesion promoter comprising a polyester resin having a hydroxyl number within the range of 28 to 250 mg KOH/g, a content of terephthalate recurring units within the range of 40 to 65 wt. % based on the amount of polyester resin, and a glass-transition temperature within the range of 40° C. to 80° C.; wherein the polyester resin comprises 20 to 50 wt. %, based on the amount of polyester resin, of recurring units of neopentyl glycol
wherein the promoted membrane is suitable for use in single-ply roofing applications.

US Pat. No. 11,111,371

HIGH FLOW AUTOMOTIVE EXTERIOR COMPOUNDS WITH EXCELLENT SURFACE APPEARANCE

BOREALIS AG, Vienna (AT)...


1. A composition comprising a modified polypropylene composition and an inorganic filler, wherein the modified polypropylene composition is obtained by treatment of a polypropylene composition with a peroxide (PO), the polypropylene composition comprising:(a) a heterophasic composition, comprising:(a1) a (semi)crystalline polypropylene, and
(a2) an elastomeric ethylene/propylene copolymer dispersed in the (semi)crystalline polypropylene,

(b) a plastomer being a copolymer of ethylene and at least one C4 to C20 ?-olefin, and
(c) optionally a high flow polypropylene, the high flow polypropylene having a higher melt flow rate MFR2 (230° C.), measured according to ISO 1133, than the (semi)crystalline polypropylene,
wherein the modified polypropylene composition has:(i) a melt flow rate MFR2 (230° C.) measured according to ISO 1133 above 32 g/10 min, and
(ii) an intrinsic viscosity determined according to DIN ISO 1628/1 (in Decalin at 135° C.) of the xylene soluble fraction below 2.30 dl/g and
(iii) an intrinsic viscosity determined according to DIN ISO 1628/1 (in Decalin at 135° C.) of the xylene insoluble fraction below 1.05 dl/g.


US Pat. No. 11,112,401

METHOD FOR DETERMINING THE CELL MEDIATED IMMUNE COMPETENCE OF A SUBJECT

Oxford Immunotec Limited,...


1. A method for determining the cell mediated immune competence of a subject, the method comprising conducting a cell-mediated immunoassay (CMI) on a sample comprising immune cells from the subject, and detecting in vitro an immune response to a pool of peptides, wherein the pool of peptides is derived from at least three but not more than five viral antigens selected from hexon protein of human adenovirus 3, matrix protein 1 of influenza virus, BZLF-1 protein of Epstein Barr virus, nucleocapsid protein of influenza virus, and fusion glycoprotein G0 of respiratory syncytial virus.
US Pat. No. 11,110,087

COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR

GENENTECH, INC., South S...


1. A method for treating lymphoma or leukemia in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in dosing cycles comprising escalating doses, wherein the escalating doses comprise a dose of 100 mg of GDC-0199 per day, followed by orally administering to the patient a dose of 200 mg of GDC-0199 per day, followed by orally administering to the patient a dose of 400 mg of GDC-0199 per day.
US Pat. No. 11,112,402

REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS

Alexion Pharmaceuticals, ...


1. A method for treating a patient, the method comprising administering to a patient in need thereof one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy, wherein the patient has been determined to have a paroxysmal nocturnal hemoglobinuria (PNH) Type II white blood cell population that is between 1.2% and 65.3%, inclusive of 1.2% and 65.3%, of the patient's total granulocytes.
US Pat. No. 11,110,088

IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE

Acerta Pharma B.V., Oss ...


1. A compound selected from the group consisting of:4-[8-amino-3-[(1S)-1-(but-2-ynoylamino)ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(2-pyridyl)benzamide;
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-[4-(trifluoromethyl)-2-pyridyl]benzamide;
4-[8-amino-3-[(1S)-1-[but-2-ynoyl(methyl)amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(2-pyridyl)benzamide;
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-thiazol-2-yl-benzamide;
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-(but-2-ynoylamino)ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[but-2-ynoyl(methyl)amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[but-2-ynoyl(methyl)amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[but-2-ynoyl(methyl)amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[[(E)-4-methoxybut-2-enoyl]-methyl-amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[[(E)-4-methoxybut-2-enoyl]amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-(but-2-ynoylamino)ethyl]imidazo[1,5-a]pyrazin-1-yl]-N-[4-(trifluoromethyl)-2-pyridyl]benzamide;
4-[8-amino-3-[(1S)-1-(but-2-ynoylamino)ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-[4-(trifluoromethyl)-2-pyridyl]benzamide;
4-[8-amino-3-[(1S)-1-[[(E)-4-methoxybut-2-enoyl]amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-(5-methyl-2-pyridyl)benzamide;
4-[8-amino-3-[(1S)-1-[but-2-ynoyl(methyl)amino]ethyl]imidazo[1,5-a]pyrazin-1-yl]-2-methoxy-N-[4-(trifluoromethyl)-2-pyridyl]benzamide; and
(S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-4-yl)benzamide.

US Pat. No. 11,111,373

POLYMETHACRYLATE COMPOSITION AND OPTICAL DEVICE MADE THEREFROM, AND DISPLAY APPARATUS

Chi Mei Corporation, Tai...


1. A polymethacrylate composition, comprising:50 to 85 parts by weight of methacrylate polymer, wherein the methacrylate polymer includes methacrylate monomer unit and acrylate monomer unit and has a weight average molecular weight in a range between 20,000 and 200,000;
15 to 50 parts by weight of styrene maleic anhydride copolymer;
200 ppm-900 ppm of aromatic compound having a phosphite group; and
10,000 ppm-50,000 ppm of an UV absorber, wherein a flash point of the UV absorber is 240° C. or higher,
wherein the total amount of the methacrylate polymer and the styrene maleic anhydride copolymer is 100 parts by weight, and the styrene maleic anhydride copolymer includes 65 wt %-85 wt % of styrene monomer unit, 15 wt %-35 wt % of maleic anhydride monomer unit, and 0-20 wt % of second copolymerizable monomer unit.

US Pat. No. 11,112,403

ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR

PROGENITY, INC., San Die...


1. A method for determining levels of free and dissociated PlGF in a biological sample from a pregnant human female subject, the method comprising:(a) isolating a first aliquot of the biological sample for the detection of PlGF-f and a second aliquot of the biological sample for the detection of PlGF-d;
(b) determining an amount of PlGF-f in the first aliquot;
(c) applying a treatment to the second aliquot to dissociate PlGF complexes; and
(d) determining an amount of PlGF-d in the second aliquot.

US Pat. No. 11,111,631

METHOD FOR PRODUCING FIBROUS CELLULOSE, AND FIBROUS CELLULOSE

OJI HOLDINGS CORPORATION,...


1. A method for producing fibrous cellulose having a fiber width of 1000 nm or less, comprising:(A) introducing phosphoric acid groups into cellulose fibers to form crosslinked structures via the phosphoric acid groups, so as to obtain crosslinked phosphorylated cellulose fibers,
(B) breaking some or all of the crosslinked structures to obtain crosslink-broken phosphorylated cellulose fibers, and
(C) performing a mechanical treatment on the crosslink-broken phosphorylated cellulose fibers to obtain fibrous cellulose having a fiber width of 1000 nm or less, wherein
in the step (A), crosslinked structures in an amount of 0.05 mmol/g or more and 2.0 mmol/g or less are formed,
in the step (B), 50 mol % or more of the crosslinked structures are broken, and
the step (B) is performing the hydrolysis of the crosslinked structures in an aqueous solvent with pH 3 or more.

US Pat. No. 11,112,404

METHOD FOR OBTAINING INFORMATION OF TEST SUBSTANCE

SYSMEX CORPORATION, Hyog...


1. A method for obtaining information of a test substance, the method comprising:forming a complex by causing a capture substance to bind to a test substance in a specimen;
selectively collecting at least the complex from the specimen;
immobilizing the complex collected from the specimen, onto a base plate; and
obtaining information regarding a structure of the test substance from the complex immobilized on the base plate.

US Pat. No. 11,109,578

HUMANIZED IL-4 AND IL-4RA ANIMALS

REGENERON PHARMACEUTICALS...


1. A mouse embryonic stem (ES) cell, comprising a replacement of a genomic DNA of a mouse IL-4 gene at an endogenous mouse IL-4 locus with a nucleic acid sequence of a human IL-4 gene to form a modified IL-4 gene, wherein the modified IL-4 gene encodes a human IL-4 protein and comprises exon 1 starting from the ATG initiation codon through exon 4 of the human IL-4 gene, and wherein expression of the modified IL-4 gene is under control of mouse regulatory elements at the endogenous mouse IL-4 locus.
US Pat. No. 11,111,376

FLAME-RETARDED STYRENE-CONTAINING FORMULATIONS


1. A composition comprising:an impact modified styrene-containing polymer; wherein the impact modified styrene-containing polymer is selected from the group consisting of acrylonitrile-butadiene-styrene (ABS) and high impact polystyrene (HIPS);
at least one bromine-containing flame retardant;
at least one metal hypophosphite salt Mq+(H2PO2)q, wherein M indicates a metal cation with valence q; and
at least one anti-dripping agent,
wherein the total concentration of the bromine-containing flame retardant and the metal hypophosphite is less than 28% by weight based on the sum of all components in the composition, wherein the bromine concentration of the composition is from 9.5 to 15.5% by weight based on the total weight of the composition, wherein the composition is antimony-free and meets UL-94 V-1/1.6 mm or UL-94 V-0/1.6 mm test requirements.

US Pat. No. 11,111,633

TISSUE PRODUCTS HAVING MACROFOLDS


1. A tissue product having a machine direction (MD) and a cross-machine direction (CD), a first upper surface and an opposed bottom surface, the product comprising:a first tissue ply having a basis weight from about 10 to about 45 grams per square meter (gsm) and sheet bulk greater than about 5 cubic centimeters per gram (cc/g) and a first MD length,
a second tissue ply having a basis weight from about 10 to about 45 grams per square meter (gsm) and sheet bulk greater than about 5 cubic centimeters per gram (cc/g) and a second MD Length,
a plurality of substantially CD orientated lines of perforation spaced apart from one another in the MD and defining a plurality of sheets therebetween, the sheets having a sheet length (L);
wherein the first MD Length is substantially equal to the sheet length (L) and the second MD Length is at least about 150 percent of the sheet length (L).

US Pat. No. 11,111,377

RESIN COMPOSITION

LG CHEM, LTD., Seoul (KR...


1. A resin composition, comprising:(1) 80 wt % to 99.8 wt % of a butadiene-based graft copolymer mixture;
(2) 0.1 wt % to 10 wt % of a graft copolymer comprising a derived unit from a polyolefin-based polymer, a derived unit from a vinyl cyanide compound and a derived unit from an aromatic vinyl-based compound; and
(3) 0.1 wt % to 10 wt % of an alpha olefin-based copolymer,
wherein (1) the butadiene-based graft copolymer mixture is an ABS-based graft copolymer composition comprising (A) a first butadiene-based graft copolymer comprising 40 wt % to 70 wt % of a butadiene-based rubbery polymer core and 30 wt % to 60 wt % of a graft shell comprising a derived unit from a vinyl cyanide compound and a derived unit from an aromatic vinyl compound; and (B) a second butadiene-based graft copolymer comprising 5 wt % to 30 wt % of a butadiene-based rubbery polymer core and 70 wt % to 95 wt % of a graft shell comprising a derived unit from a vinyl cyanide compound and a derived unit from an aromatic vinyl compound, and further comprising (C) a copolymer comprising a derived unit from a vinyl cyanide compound and a derived unit from an aromatic vinyl-based compound.

US Pat. No. 11,110,093

SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION

INDIVIOR UK LIMITED, Hul...


1. An injectable pharmaceutical composition comprising from about 10 wt % to about 30 wt % of risperidone base suspended in a gel comprising: (i) from about 40 wt % to about 60 wt % of a copolymer of lactic acid and glycolic acid, wherein the lactic acid to glycolic acid monomer ratio is from about 100:0 to about 60:40, and wherein the copolymer has a number average molecular weight from about 5,000 Daltons to about 30,000 Daltons, and (ii) benzyl benzoate, benzyl alcohol, ethyl benzoate, triacetin, N-methyl-2-pyrrolidone, or a combination of two or more thereof.
US Pat. No. 11,112,408

BIOSENSOR FOR DETECTING THE PRESENCE OF BACTERIA

CENTRE NATIONAL DE LA REC...


1. A biosensor for detecting the presence and/or measuring the concentration of at least one biological agent, comprising a support on which a barcode is placed, at least one area of which is functionalized by at least one aptamer capable of selectively immobilizing said biological agent, said aptamer itself being linked, directly or indirectly, to a coloring molecule, wherein:said coloring molecule is linked via a labile bond to the aptamer and is able to produce color following an enzyme attack causing a break of said labile bond; or, alternatively,
said coloring molecule is an antibiotic covalently bonded to the aptamer and is able to produce color or to change color following the immobilization of the biological agent by said aptamer.

US Pat. No. 11,110,094

RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION

Shandong Luye Pharmaceuti...


1. A pharmaceutical composition comprising:a pharmaceutically active component selected from risperidone or a salt thereof, 9-hydroxy risperidone or a salt thereof; and
a polymer blend consisting of a first uncapped poly(lactide-co-glycolide) and a second uncapped poly(lactide-co-glycolide), wherein the first uncapped poly(lactide-co-glycolide) has a molar ratio of lactide to glycolide of 65:35 to 90:10; and the second uncapped poly(lactide-co-glycolide) has a molar ratio of lactide to glycolide of 50:50 to 75:25; and
wherein the pharmaceutical composition is prepared by forming a plurality of microspheres, each microspheres consisting of the pharmaceutically active component encapsulated in the polymer blend.

US Pat. No. 11,111,379

POLYMER NANOCOMPOSITE COMPRISING POLY(ETHYLENE TEREPHTHALATE) REINFORCED WITH AN INTERCALATED PHYLLOSILICATE


1. An intercalated phyllosilicate having a structure of layers and comprising an intercalating agent between the layers, wherein the intercalating agent is a polyester of a molecular weight of 274 to 30,000 g/mol selected from polyadipate, polyphthalate, and a mixture thereof, and wherein the phyllosilicate is other than a phyllosilicate modified through ionic interchange.
US Pat. No. 11,112,409

SYSTEMS AND COMPOSITIONS FOR DIAGNOSING PATHOGENIC FUNGAL INFECTION AND METHODS OF USING THE SAME

THE REGENTS OF THE UNIVER...


1. A method of diagnosing a subject with a pathogenic fungal infection from the genus Candida, comprising:a) exposing a sample from the subject to at least one substrate of at least one secreted aspartyl protease (Sap), wherein the at least one substrate comprises at least one enzymatic cleavage site recognizable by the at least one Sap, and wherein the at least one Sap comprises at least about 90% sequence homology to SEQ ID NO: 5 or SEQ ID NO: 6;
b) detecting the presence, absence and/or quantity of enzymatic cleavage of the substrate by the at least one Sap in the sample; and
c) correlating the presence, absence and/or quantity of enzymatic cleavage of the substrate by the at least one Sap to a probability or likelihood that the subject has the pathogenic fungal infection relative to a measurement of a control sample taken from a subject known to have or not to have the pathogenic fungal infection,
wherein the at least one substrate of SEQ ID NO: 5 comprises a peptide with 85% sequence homology to SEQ ID NO: 31 and wherein the at least one substrate of SEQ ID NO: 6 comprises a peptide with 85% sequence homology to SEQ ID NO: 32.

US Pat. No. 11,111,380

COMPOSITION AND THERMOPLASTIC MOLDING COMPOUND HAVING GOOD NOTCH IMPACT STRENGTH AND IMPROVED MELT STABILITY

Covestro Deutschland AG, ...


1. A composition for production of a thermoplastic moulding compound, wherein the composition comprises the following constituents:A) 30% to 90% by weight of at least one polymer selected from the group consisting of aromatic polycarbonate, aromatic polyester carbonate, and aromatic polyester based on the total weight of the composition,
B) 5% to 65% by weight of a polymer free of epoxy groups based on the total weight of the composition, the polymer free of epoxy groups consisting ofB1) a rubber-modified vinyl (co)polymer prepared by the emulsion polymerization method and
B2) optionally, a rubber-free vinyl (co)polymer,

C) 0.5% to 10% by weight of a block or graft polymer comprising structural elements deriving from styrene and at least one epoxy-comprising vinyl monomer based on the total weight of the composition,
D) 0.001% to 20% by weight of one or more further additives based on the total weight of the composition,

wherein component A has a proportion by weight of phenolic OH groups of 50 to 2000 ppm,
wherein component C has a weight ratio of structural elements deriving from styrene to those deriving from epoxy-comprising vinyl monomer of 100:1 to 1:1,
and wherein at least one of the composition constituents comprises a Brønsted-acidic and/or Brønsted-basic compound.
US Pat. No. 11,112,410

METHODS FOR CAPTURING, ISOLATION, AND TARGETING OF CIRCULATING TUMOR CELLS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF

PRESIDENT AND FELLOWS OF ...


1. A method for capturing circulating tumor cells (CTCs) from a biological fluid of a subject, comprising; contacting the biological fluid with a C-type lectin molecule comprising a carbohydrate recognition domain (CRD) of mannose binding lectin attached to a surface.
US Pat. No. 11,110,096

COMBINATION THERAPIES

Infinity Pharmaceuticals,...


1. A method of treating a hematological cancer in a human subject in need thereof, comprising administering to the subject a combination of (S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (Compound 1), or a pharmaceutically acceptable salt or hydrate thereof, and ABT-199, or a pharmaceutically acceptable salt thereof;wherein Compound 1, or a pharmaceutically acceptable salt or hydrate thereof, is administered at a dose of about 15 mg to about 75 mg;
wherein ABT-199, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 10 mg to about 400 mg; and
wherein the hematological cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL, indolent NHL (iNHL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell lymphoma (TCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), follicular lymphoma (FL), and Richter's syndrome.

US Pat. No. 11,111,381

POLYCARBONATE RESIN COMPOSITION FOR OPTICAL COMPONENT, AND OPTICAL COMPONENT

Mitsubishi Engineering-Pl...


1. A polycarbonate resin composition, comprising:100 parts by mass of a polycarbonate resin (A),
0.1 to 4 parts by mass of a polyalkylene glycol (B), and
0.005 to 0.5 parts by mass of a phosphorus-comprising stabilizer (C),
wherein the polyalkylene glycol (B) comprises 52.7 to 80 mol % of a tetramethylene glycol unit (b1), 5 to 45 mol % of a (2-methyl)ethylene glycol unit (b2), and 5 to 50 mol % of an ethylene glycol unit (b3), and
wherein the polyalkylene glycol (B) is characterized by being contained as a copolymer having the tetramethylene glycol unit (b1), the (2-methyl)ethylene glycol unit (b2), and the ethylene glycol unit (b3).

US Pat. No. 11,112,411

METHOD FOR SIMULTANEOUS QUANTIFICATION OF ALXN1210 AND ECULIZUMAB IN HUMAN SERUM OR URINE

Alexion Pharmaceuticals, ...


1. A method of detecting and quantifying the respective amounts of two antibodies having high sequence identity present together in a biological sample, wherein the antibodies are eculizumab and ravulizumab, the method comprising:(a) treating the biological sample containing the antibodies with a protease to form a proteolytic peptide mixture of the antibodies in the biological sample;
(b) analyzing a sample of the proteolytic peptide mixture by high performance liquid chromatography (HPLC) tandem mass spectrometry to detect a signature peptide from each of the antibodies in the biological sample, wherein the signature peptide for eculizumab comprises SEQ ID NO: 1, SEQ ID NO: 19, or SEQ ID NO: 20, and the signature peptide for ravulizumab comprises SEQ ID NO: 2, SEQ ID NO: 21, or SEQ ID NO:22 wherein the signature peptide comprises no more than 27 amino acids; and
(c) quantifying each antibody in the biological sample based on the signal ratio of its signature peptide to an internal control, wherein the internal control comprises a labeled form of the same signature peptide.

US Pat. No. 11,110,097

COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

The General Hospital Corp...


1. A method of treating or slowing the progression of a disease or condition in a human subject in need thereof comprising administering sublingually, intranasally, or to mucous membranes in the subject, a therapeutically effective amount of cromolyn or a salt thereof, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
US Pat. No. 11,112,412

SARS-COV-2 SURROGATE VIRUS NEUTRALIZATION ASSAY TEST KIT

NATIONAL UNIVERSITY OF SI...


1. A kit for detecting neutralizing antibodies to a severe acute respiratory syndrome-related coronavirus (SARSr-COV), comprising:(i) a SARS-COV-1 or -2 spike protein or an ACE2-binding fragment of a SARS-COV-1 or -2 spike protein,
(ii) a human ACE2 protein or a SARS-CoV-1 or -2 receptor binding domain (RBD) binding fragment of a human ACE2 protein thereof which binds specifically to the spike protein or the fragment thereof of (i), and
a detection entity comprising a horseradish peroxidase, for detecting interaction between the spike protein or the ACE2-binding fragment of (i) and the human ACE2 protein or RBD binding fragment of (ii),
wherein the spike protein or the ACE2-binding fragment of (i) is conjugated to the detection entity; and the human ACE2 protein or the RBD binding fragment of (ii) is immobilised on a solid support.

US Pat. No. 11,110,098

METHODS AND MEDICAMENTS FOR THE TREATMENT OF RENAL CELL CARCINOMA

University of Kansas, La...


1. A method of treating a subject suffering from clear cell renal cell carcinoma, the method comprisingadministering to the subject an effective amount of a compound selected from OPC31260, OPC41061, a pharmaceutically acceptable salt of either thereof, or a mixture of any two or more thereof;
wherein the effective amount is an amount effective for treating clear cell renal cell carcinoma.

US Pat. No. 11,111,383

RESIN COMPOSITION AND ARTICLE MADE THEREFROM

ELITE MATERIAL CO., LTD.,...


1. A resin composition, comprising: a vinyl-containing polyphenylene ether resin, a bis(vinylphenyl)ethane and a modification of divinylbenzene, wherein the modification of divinylbenzene comprises a copolymer, a prepolymer or a derivative of divinylbenzene and a following component: methyl methacrylate resin, triallyl isocyanurate resin, triallyl cyanurate resin, ethylstyrene or a combination thereof.
US Pat. No. 11,112,413

MULTIPLEXED IMMUNOHISTOCHEMISTRY USING RECOMBINANT ANTIBODIES WITH EPITOPE TAGS

Ventana Medical Systems, ...


1. A kit comprising:(a) at least one epitope-tagged antibody, wherein the at least one epitope-tagged antibody comprises an antibody and at least one epitope tag construct, and
(b) detection reagents for detecting the at least one epitope-tagged antibody,
wherein the detection reagents comprise at least one anti-tag antibody, wherein the at least one anti-tag antibody is specific for an expressed epitope tag of the at least one epitope-tagged antibody, and
wherein the at least one epitope tag construct consists of the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

US Pat. No. 11,110,099

NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES

TherapeuticsMD, Inc., Bo...


1. A pharmaceutical composition comprising: a fill material encapsulated in a capsule, the fill material comprising:a. two active pharmaceutical ingredients, the active pharmaceutical ingredients being about 1 mg of 17?-estradiol and about 100 mg of progesterone, wherein at least about 90% of the 17?-estradiol is solubilized, and wherein a first portion of the progesterone is solubilized and a second portion of the progesterone is micronized;
b. a solubilizing agent for the active pharmaceutical ingredients, the solubilizing agent comprising:i. a medium chain oil comprising mono- and diglycerides; and
ii. at least one of lauroyl macrogol-32 glycerides or lauroyl polyoxyl-32 glycerides;


wherein the 17?-estradiol and the progesterone in the capsule are present in the solubilizing agent; wherein the second portion of the progesterone is uniformly dispersed in the solubilizing agent; wherein the progesterone has a solubility in the solubilizing agent of at least about 73 mg/g, and the 17?-estradiol has a solubility in the solubilizing agent of at least about 10 mg/g; and wherein the progesterone comprises about 30% to about 35% by weight of the fill material, and the 17?-estradiol comprises about 0.1% to about 0.4% by weight of the fill material.
US Pat. No. 11,111,384

POLYAMIDE RESIN COMPOSITION FOR BLOW-MOLDED PRODUCTS EXPOSED TO HIGH-PRESSURE HYDROGEN, AND BLOW-MOLDED PRODUCT

Toray Industries, Inc., ...


1. A polyamide resin composition for a blow-molded article exposed to high-pressure hydrogen gas,the polyamide resin composition comprising:
70 to 99 parts by weight of a polyamide 6 resin (A);
1 to 30 parts by weight of an impact modifier (B); and
0.005 to 1 parts by weight of a metal halide (C) with respect to a total of 100 parts by weight of the polyamide 6 resin (A) and the impact modifier (B),
wherein the polyamide 6 resin (A) has a relative viscosity (?r) of 3.3 to 7.0 at a temperature of 25° C. in a 98% sulfuric acid solution having a resin concentration of 0.01 g/ml,
the impact modifier (B) comprising an ethylene/?-olefin copolymer modified with an unsaturated carboxylic acid and/or its derivative, wherein the derivative of an unsaturated carboxylic acid is an unsaturated carboxylic acid compound having a carboxyl group, metal salts, acid halides, esters, acid anhydrides, amides, and imides of unsaturated carboxylic acids,
an amount of the unsaturated carboxylic acid and/or its derivative introduced from the modification is 0.1 to 2.5 parts by weight with respect to 100 parts by weight of the ethylene/?-olefin copolymer modified with the unsaturated carboxylic acid and/or its derivative,
using the following measurement, wherein the polyamide resin composition has a melt tension of 20 mN or more when measured at 260° C. and a take-up speed at strand break of 50 m/min or more when measured using Capillograph 1C (cylinder inner diameter: 9.55 mm, orifice length: 10.0 mm, inner diameter: 1.0 mm), pellets of the polyamide resin composition are filled in a cylinder in which a test temperature is set to 260° C., the pellets are compacted and held for 20 minutes to melt the pellets, and the melted resin is then extruded in a strand form at 260° C. from an orifice at a piston speed of 10 mm/min, winding the strand through a lower circular guide of a tension detection pulley at a take-up speed of 10 m/min, and a tension to be detected was taken as the melt tension of the polyamide resin composition, and
after the melt tension was stabilized at a take-up speed of 10 m/min, the strand was wound while the take-up speed was accelerated at an acceleration of 400 m/min2, and a take-up speed at the time when the strand was broken was taken as the take-up speed at strand break of the polyamide resin composition.

US Pat. No. 11,112,414

BIOMARKER OF REHOSPITALIZATION AFTER HEART FAILURE

INSERM (INSTITUTE NATIONA...


1. A method for avoiding rehospitalization and treating a heart failure patient with a clinical diagnosis of heart failure, wherein said method comprisesobtaining a biological sample selected from the group consisting of blood, plasma, and urine from said patient,
measuring the concentration of IGFBP2 in said sample obtained from said patient with the clinical diagnosis of heart failure, and
comparing the concentration of IGFBP2 measured in said measuring step to a threshold value derived from the concentration of IGFBP2 in blood samples taken from a group of patients wherein each of the patients in the group has one or more stages of heart failure selected from the group consisting of stage I, stage II, stage III and stage IV, according to the New York Heart Association (NYHA) heart failure classification system,
rehospitalizing said patient with the clinical diagnosis of heart failure if the measured concentration exceeds the threshold value, and
administering to said patient with the clinical diagnosis of heart failure at least one treatment selected from the group consisting of an effective amount of a beta-blocker, an effective amount of an angiotensin-converting enzyme inhibitor, an effective amount of an angiotensin receptor blocker, an effective amount of an aldosterone antagonist, an implantable cardiac defibrillator, a cardiac resynchronization therapy, an implantable left ventricular assistive device and a heart transplant,
wherein the clinical diagnosis of heart failure is a diagnosis of heart failure with either reduced or preserved ejection fraction.

US Pat. No. 11,114,228

MAGNETIC POWDER COMPOSITE, ANTENNA AND ELECTRONIC DEVICE, AND METHOD FOR PRODUCING THE SAME

DOWA ELECTRONICS MATERIAL...


1. A magnetic powder composite, consisting of:a metal magnetic powder; and
one or more elements selected from carboxylic acid or its anhydride, aromatic carboxylic acid ester, and a derivative thereof, and having a molecular weight of 500 or less and a carbon number of from 4 to 30, as a coating material,
having a property that real part ?? of permeability is 1.45 or more, tan ?? is 0.1 or less, tan ?? is 0.05 or less at a measuring frequency of 2 GHz, when a magnetic powder composite is prepared by adding 5 parts by mass of one or more elements selected from the carboxylic acid or its anhydride, the aromatic carboxylic acid ester, and the derivative thereof to 100 parts by mass of the metal magnetic powder, and 30 vol % of the magnetic powder composite is contained in a thermoplastic resin in which the tan ?? is 0.05 or less at 1 MHz specified in IEC 60250 or JIS C 2138: 2007,

whereinthe coating material is one or more elements selected from the group consisting of phthalic acid, phthalic anhydride, maleic acid, maleic anhydride, succinic acid, succinic anhydride, malonic acid, fumaric acid, glutaric acid, azelaic acid, sebacic acid, benzoic acid, dimethyl phthalate, and a derivative thereof, and
a surface of the metal magnetic powder is coated with the coating material.

US Pat. No. 11,109,587

LIMONENE: FORMULATION AND INSECTICIDE USE

ARYSTA LIFESCIENCE BENELU...


1. An insecticidal or acaricidal composition, comprisingan emulsifiable concentrate comprising more than 50 wt % limonene as an active ingredient,
between 12-20 wt % of an emulsifying fatty alcohol ethoxylate surfactant having a hydrophilic-lipophilic balance (HLB) between 7 and 12, and no emulsifying surfactant having an HLB of 12 to 16,
less than 10 wt % solvent,
between 15-25 wt % of an anionic surfactant wetting agent;
wherein all weights are based on the total weight of the composition,
wherein the insecticidal or acaricidal emulsifiable concentrate, upon dilution with water and spraying as a water diluted spray, provides a dose rate of 60 g to 1,800 g limonene per hectare such that the composition is effective in the treatment of Acari or mites, Coccoidea or scales and Aleyrodidae or white flies, and
wherein the insecticidal or acaricidal emulsifiable concentrate is stable after 14 days at a temperature of 0° C., ?5° C., room temperature or 54° C.

US Pat. No. 11,111,385

SILICONE COMPOSITION

OSRAM OLED GmbH, Regensb...


1. A silicone composition comprising a multiphase mixture of a low-refractive silicone having a refractive index n25D589 less than 1.45 and a high-refractive silicone having a refractive index n25D589 greater than 1.50, wherein a proportion of high-refractive silicone is 0.1 to 5.0 mass percent in relation to a total mass of high-refractive and low-refractive silicone, the high-refractive silicone forms inclusions within the low-refractive silicone, the silicone composition is free of converter particles, the silicone composition comprises reflector particles, and a proportion of the reflector particles is less than 1 mass percent in relation to the total mass of high-refractive, low-refractive silicone and reflector particles.
US Pat. No. 11,109,588

STABLE LIQUID FORMULATIONS AND METHODS OF USING THE SAME

GOWAN COMPANY, L.L.C., Y...


1. A liquid pesticide formulation comprising:a) halosulfuron-methyl;
b) one or more diluent(s), where the diluent(s) is a liquid comprising:i) a first carbon structure of at least six carbon atoms, the first carbon structure being a substituted or unsubstituted, saturated or unsaturated, linear or branched alkyl or heteroalkyl;
ii) optionally one or more glyceryl, carbonyl, phenyl, sulfonyl, or phosphonyl group(s) on the first carbon structure,wherein if the first carbon structure of the diluent comprises a hydroxyl group(s), the hydroxyl group(s) is adjacent to a carbonyl, phenyl, sulfonyl, or phosphonyl group(s);


c) optionally, one or more surfactant(s), wherein the one or more surfactant(s) comprise:i) a second carbon structure of at least six carbon atoms, wherein the second carbon structure is a substituted or unsubstituted, saturated or unsaturated, linear or branched alkyl or heteroalkyl;
ii) optionally one or more glyceryl, carbonyl, phenyl, sulfonyl, or phosphonyl group(s) on the second carbon structure,wherein if the second carbon structure of the surfactant comprises a hydroxyl group(s), the hydroxyl group(s) is adjacent to a carbonyl, phenyl, sulfonyl, or phosphonyl group(s);


d) one or more rheology modifier(s); and
e) optionally, one or more buffer(s);

wherein the liquid pesticide formulation exhibits 5% (w/w) or less loss of halosulfuron-methyl upon storage for 8 weeks at 40° C. measured using quantitative chromatography.
US Pat. No. 11,110,101

PROSTATE FUNCTION SUPPORT FORMULA

Innovus Pharmaceuticals, ...


1. A method to improve prostate function in a man in need thereof comprising administering a unit dosage form to the man wherein the unit dosage form consists of the active ingredients:300 mg±15 mg of Saw Palmetto;
450 mg±22.5 mg of Beta-Sitosterol;
150 mg±7.5 mg of Pygeum africanum;
75 mg±3.75 mg of Green Tea extract
15 mg±0.75 mg of Lycopene; and
30 mg±1.5 mg of Stinging Nettle.

US Pat. No. 11,109,590

POTENTIATED ANTIMICROBIAL COMPOSITION FOR THE ANTIMICROBIAL TREATMENT OF BIOFILMS

CuraSolutions GmbH, Vien...


1. A method for an antimicrobial and/or antioxidative treatment of biofilms in an aqueous liquid, the method comprising:introducing into the aqueous liquid a composition which comprises:
(a) a micelle forming solubilizate which comprises 5 to 40% by weight of at least one plant extract, 30 to 85% by weight of at least one emulsifier with an HLB value of 8 to 18, and water, and
(b) 13 to 19% by weight H2O2 and 1 to 2.5% by weight L(+) lactic acid, wherein the aqueous liquid is not a human or animal body fluid.

US Pat. No. 11,111,388

PRECIPITATED CALCIUM CARBONATE WITH IMPROVED RESISTANCE TO STRUCTURAL BREAKDOWN

OMYA INTERNATIONAL AG, O...


1. A process for producing precipitated calcium carbonate comprising the steps of:a) providing a calcium oxide containing material,
b) providing an aqueous solution,
c) providing a gas comprising carbon dioxide,
d) preparing a milk of lime comprising Ca(OH)2 by mixing the aqueous solution of step b) with the calcium oxide containing material of step a),
e) carbonating the milk of lime obtained from step d) with the gas of step c) to form an aqueous suspension of precipitated calcium carbonate, wherein:
the carbonation is carried out in the presence of a static gas bubble comminution unit that is located in the milk of lime and the gas of step c) is flushed around and/or through the static gas bubble comminution unit.

US Pat. No. 11,109,591

SINGLE PHASE LIQUIDS OF ALKANOLAMINE SALTS OF DICAMBA

Taminco BVBA, Ghent (BE)...


1. A salt comprising obtained by combining an amine and a carboxylic acid herbicide;wherein the amine comprises 3-(dimethylamino)propionitrile (DMAPN) and the herbicide comprises 2,4-dichlorophenoxyacetic acid (2,4-D), 3,6-dichloro-2-methoxybenzoic acid (dicamba), glufosinate, or glyphosate.

US Pat. No. 11,109,592

SELECTIVE WEED CONTROL METHODS

Corteva Agriscience LLC, ...


1. A method for the selective post-emergent control of undesirable vegetation in the presence of a crop selected from the group consisting of sunflowers, sorghum, yellow mustard, spring kale, spring turnip, spring rutabaga, and spring Winfred forage brassica, which comprises applying a herbicidally effective amount of 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or an agriculturally acceptable ester or salt thereof directly to the undesirable vegetation or to the locus thereof or to the area where control of the undesirable vegetation is desired,wherein the 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or agriculturally acceptable ester or salt thereof is applied at a rate of up to 10 g ae/ha,
wherein the 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or an agriculturally acceptable ester or salt thereof is not combined with aminopyralid,
wherein the degree of injury to the crop is less than 20% rated visually, and
wherein the undesirable vegetation is selected from a group consisting of Amaranthus spp., Fumaria spp., Conyza spp., Geranium spp., Ambrosia spp., Malva spp., Lamium spp., cleavers (Galium aparine), chickweed (Stellaria media), hempnettle (Galeopsis tetrahit), lamb's-quarters (Chenopodium album), Mexican pricklepoppy (Argemone mexicana), stork's-bill (Erodium cicutarium), volunteer flax (Linum usitatissimum), and volunteer alfalfa (Medicago sativa).

US Pat. No. 11,111,390

SURFACE-MODIFIED EFFECT PIGMENT AND NAIL VARNISH COMPOSITION

ECKART GmbH, Hartenstein...


1. A nail varnish composition comprising:a) at least one effect pigment surface-modified with a starting material (additive), wherein the effect pigment comprises a PVD aluminum pigment in platelet form and optionally comprises at least one coating applied to the PVD aluminum pigment, the PVD aluminum pigment having an average thickness h50 ranging from 13 nm to 60 nm, and wherein the starting material (additive) used for surface modification of the PVD aluminum pigment or the coating comprises phosphoric acid cetyl ester in an amount ranging from 10% by weight to 50% by weight based on the total weight of the optionally coated PVD aluminum pigment;
b) at least one hydrocarbon resin as binder; and
c) at least one non-aqueous solvent.

US Pat. No. 11,111,391

COATED MAGNESIUM OXIDE PARTICLES AND METHOD OF PRODUCING THE SAME, AND THERMAL CONDUCTIVE RESIN COMPOSITION

Ube Material Industries, ...


1. Coated magnesium oxide particles in which the surface of magnesium oxide particles is coated with at least one of a fatty acid and a fatty acid metal salt, whereina raw material of the magnesium oxide particles is a sintered body of magnesium oxide,
X in relation to particles is defined as X=[a BET specific surface area diameter calculated from a BET specific surface area of the particles] ÷ [D50 of the particles], provided that D50 is a particle diameter at 50% accumulation in a cumulative particle size distribution of the particles,
the magnesium oxide particles have X of less than 0.2 and D50 of 5 to 100 ?m, and
the coated magnesium oxide particles have X of 0.2 or more, D50 of 5 to 100 ?m, and oil absorption of less than 25 mL/100 g.

US Pat. No. 11,109,595

MICROALGAE-BASED COMPOSITIONS FOR BENEFITING PLANTS AND METHODS OF APPLICATION

Heliae Development, LLC, ...


1. A method of enhancing the active carbon score of a soil, comprising administering an amount of a microalgae material to the soil,wherein the amount of microalgae material is effective to increase the active carbon score of the soil by at least 10% over a period of 10-15 days;
the microalgae material comprises Chlorella cells and/or Parachlorella kessleri cells that have been lysed; and
the microalgae material is provided as a liquid formulation composition comprising 0.1-15% solids from one or more cultures of the microalgae that is applied in a concentration of 0.25 gal/acre to 4 gal/acre for a period of 8-20 weeks.

US Pat. No. 11,114,237

METHOD OF IMPROVING THE COERCIVITY OF ND—FE—B MAGNETS

YANTAI SHOUGANG MAGNETIC ...


1. A method of improving coercivity of an Nd—Fe—B magnet, said method comprising the steps of:providing an Nd—Fe—B magnet having a first surface and a second surface;
forming a first solidified film of at least one pure heavy rare earth element attached to the first surface of the Nd—Fe—B magnet to prevent a reduction in corrosion resistance caused by oxygen and fluorine and hydrogen;
wherein said step of forming the first solidified film comprises depositing a first layer of at least one pure heavy rare earth element powder selected from the group consisting of Dy, Tb, an alloy of Dy and Tb, and mixtures thereof onto the first surface of the Nd—Fe—B magnet under an inert atmosphere, then heating the first surface of the Nd—Fe—B magnet including the first layer to form the first solidified film of the powders attached to the first surface of the Nd—Fe—B magnet;
then forming a second solidified film of at least one pure heavy rare earth element on the second surface of the Nd—Fe—B magnet;
wherein said step of forming the second solidified film comprises depositing a second layer of at least one pure heavy rare earth element powder selected from the group consisting of Dy, Tb, an alloy of Dy and Tb, and mixtures thereof onto the second surface of the Nd—Fe—B magnet under an inert atmosphere and then heating the second surface of the Nd—Fe—B magnet including the second layer to form the second solidified film of the powders on the second surface of the Nd—Fe—B magnet;
subjecting the Nd—Fe—B magnet including the first solidified film and the second solidified film to a diffusion treatment in a vacuum or an inert atmosphere; and
subjecting the Nd—Fe—B magnet including the first solidified film and the second solidified film to an aging treatment in the vacuum or the inert atmosphere.

US Pat. No. 11,109,596

MICROORGANISMS FOR THE PRODUCTION OF INSECT PHEROMONES AND RELATED COMPOUNDS

Provivi, Inc., Santa Mon...


1. A recombinant Yarrowia lipolytica capable of producing a mono- or poly-unsaturated C6-C24 fatty alcohol from an endogenous or exogenous source of saturated C6-C24 fatty acid, comprising:a heterologous nucleic acid molecule encoding and expressing a Helicoverpa fatty acyl desaturase that catalyzes the conversion of a saturated C6-C24 fatty acyl-CoA to a corresponding mono- or poly-unsaturated C6-C24 fatty acyl-CoA,
wherein the mono- or poly-unsaturated C6-C24 fatty acyl-CoA is converted to the corresponding mono- or poly-unsaturated C6-C24 fatty alcohol, and
wherein the Helicoverpa fatty acyl desaturase comprises a transmembrane desaturase sequence motif of HX3-4HX7-41(3 non-His)HX2-3(1 non-His)HHX61-189(40 non-His)HX2-3(1 non-His)HH.

US Pat. No. 11,110,109

WATER SOLUBLE O-GLYCOSYL FLAVONOID COMPOSITIONS AND METHODS FOR PREPARING SAME

ALPS Pharmaceutical Ind. ...


1. A water-soluble composition comprising an O-glycosyl flavonoid compound, L-arginine, a sugar alcohol, and an alkali salt of ascorbic acid, wherein the O-glycosyl flavonoid compound is selected from the group consisting of rutin, isoquercitrin, and hesperidin, the sugar alcohol is selected from the group consisting of maltitol, erythritol, xylitol, and sorbitol, the molar ratio between the O-glycosyl flavonoid compound and the L-arginine is 1:0.5-2.0 and the molar ratio between the glycosyl compound and the sugar alcohol is 1:4.0-12.0.
US Pat. No. 11,110,111

DEOXYNUCLEOSIDE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES

THE TRUSTEES OF COLUMBIA ...


1. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: DGUOK; TYMP; and RRM2B, and the therapeutically effective amount is between about 100 mg/kg/day and about 1000 mg/kg/day.
US Pat. No. 11,111,397

SILICA-BASED FILM-FORMING COMPOSITION, METHOD OF PRODUCING SUBSTRATE INCLUDING SILICA-BASED FILM, AND ADDITIVE ADDED TO SILICA-BASED FILM-FORMING COMPOSITION

TOKYO OHKA KOGYO CO., LTD...


1. A silica-based film-forming composition, comprising a polysilazane (A) and a solvent (S),wherein the solvent (S) comprises a nitrogen-containing polar organic solvent, and
wherein the nitrogen-containing polar organic solvent comprises a compound having a partial structure represented by Formula (S1-1):—NRs1—C(?O)—NRs2—??(S1-1)


wherein Rs1 and Rs2 are each independently a hydrogen atom or a hydrocarbon group which may include a substituent.
US Pat. No. 11,110,115

NUCLEIC ACID MOLECULE WITH ANTI-INFLAMMATORY AND ANTI-COAGULANT AND ORGAN-PROTECTIVE PROPERTIES


1. A method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of a disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur in an individual, the method comprising administering to said individual an effective amount of a nucleic acid molecule, said nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:1 or a nucleotide sequence at least 95% identical thereto or comprising the nucleotide sequence set forth as SEQ ID NO:2 or nucleotide sequence at least 95% identical thereto or a pharmaceutical composition comprising said nucleic acid molecule and a pharmaceutically acceptable carrier, adjuvant, salt, diluent and/or excipient.
US Pat. No. 11,110,372

COLD EXTRACTION METHOD FOR CANNABINOIDS AND TERPENES FROM CANNABIS BY ORGANIC SOLVENTS

Neptune Wellness Solution...


1. A method of preparing a cannabis extract comprising:a. providing cannabis plant material comprising stems, leaves, seeds, flowers or a combination thereof in an extraction chamber;
b. contacting an organic solvent at a temperature of between about 0° C. and ?80° C. with the cannabis plant material;
c. extracting at least one bioactive molecule from the cannabis plant material into the organic solvent for a first period of time, thereby producing an organic solvent comprising a cannabis extract, wherein the extraction step takes place at between about 0° C. and ?80° C.;
d. filtering or centrifuging the organic solvent and the cannabis plant material to remove solid materials; and
e. recovering the cannabis extract from the organic solvent; thereby producing the cannabis extract.

US Pat. No. 11,110,116

HYPEROSMOLAR COMPOSITION OF HYALURONIC ACID

Horus Pharma, Saint Laur...


1. A hyperosmolar ophthalmic composition comprising 0.01 to 0.2% by weight of sodium hyaluronate, 0.05 to 0.5% by weight of hydroxypropylmethyl cellulose and sodium chloride as a hyperosmolarity agent, wherein the hyperosmolar ophthalmic composition has an osmolarity of 1500 to 2000 mOsm/l and a viscosity of 15 to 100 centipoises.
US Pat. No. 11,110,117

SKIN PREPARATION COMPOSITION FOR EXTERNAL USE CONTAINING COMPLEX HYALURONIC ACID

J2KBIO CO., LTD., Cheong...


1. A skin preparation composition for external use consisting of complex hyaluronic acid and purified water,wherein the complex hyaluronic acid consisting of hyaluronic acid, sodium hyaluronate, and hydrolyzed hyaluronic acid is contained by 0.001 to 3 weight % with respect to the total composition.

US Pat. No. 11,111,402

PRINTABLE COMPOSITIONS

Hewlett-Packard Developme...


1. A printable composition, comprising:a liquid carrier; and
a radiation curable polyurethane dispersed in the liquid carrier, the curable polyurethane formed from:a polyisocyanate;
a (meth)acrylate-containing polyol including a diglycidyl ester;
a mono-alcohol having (meth)acrylate functionality; and
an amino acid, wherein the amino acid comprises one or more of, valine, glutamine, asparagine, glutamic acid, phenylalanine, and proline.


US Pat. No. 11,109,605

PROCESS FOR PRODUCING INFANT FORMULA PRODUCTS AND DAIRY PRODUCTS

Compagnie Gervals Danone,...


1. A process for producing an infant formula product and a dairy product from defatted animal milk, comprising:(a) processing the defatted animal milk into a casein stream, a whey protein stream and a lactose stream by subjecting the defatted animal milk to microfiltration (MF) to obtain a casein stream as MF retentate and subjecting the MF permeate to ultrafiltration (UF) to obtain the whey protein stream as UF retentate and the lactose stream as UF permeate;
(b) combining at least part of the whey protein stream originating from step (a) and a lactose source comprising acid whey, to obtain a recombined stream;
(c) using the recombined stream originating from step (b) in the manufacture of the infant formula product; and
(d) using at least part of the casein stream originating from step (a) and defatted animal milk in the manufacture of the dairy product.

US Pat. No. 11,110,118

FORMULATIONS FOR TREATING ACID REFLUX COMPRISING SODIUM ALGINATE

PHARAGEN LLC, Las Vegas,...


1. A method of treating acid reflux disease in an individual in need thereof, comprising administering to an individual in need thereof a pharmaceutical composition formulated as a powder consisting of:(i) one or more alginate salts, present in an amount from about 30% to 78% wt of the pharmaceutical composition,
(ii) sodium bicarbonate, present in an amount from about 1% to 10% wt of the pharmaceutical composition,
(iii) calcium carbonate, present in an amount from about 1% to 10% wt of the pharmaceutical composition,
(iv) citric acid, present in an amount from about 21% to 30% wt of the pharmaceutical composition,
(v) optionally one or more natural or artificial sweetener or flavorants; and
dissolving the powder form in liquid prior to administration to individual and wherein the composition forms alginate raft prior to administering to an individual.

US Pat. No. 11,111,403

AQUEOUS ELECTRON BEAM CURABLE COMPOSITIONS COMPRISING POLY(ALKOXYLAES)

Sun Chemical Corporation,...


1. An aqueous Electron Beam (EB) curable composition comprising at least 0.5% (w/w) and no more than 10.0% (w/w) of poly(alkylene oxide) containing substances, which are essentially free of ethylenically unsaturated groups, according to the following expression:R3—(CnH2nO)xH
where R3 can be a hydroxyl group or any organic alcohol residue (including other poly(alkylene oxide)s), n can be any number between 1 and 6, and x can be any number equal to, or greater than 2; and
further comprising any blend of acrylated polyurethane dispersions.

US Pat. No. 11,109,606

VEGAN CHEESE ANALOGUE


1. A cheese analogue, comprising water, a waxy root or tuber starch, native potato protein and a fat component, wherein the waxy root or tuber starch comprises at least 90 wt. % amylopectin; wherein the total quantity of waxy root or tuber starch is 10-24 wt. % of the total composition; and wherein the cheese analogue exhibits stretch of at least 35 cm at 80° C., at least 70 cm at 50° C., or at least 40 cm at 25° C., under standard conditions.
US Pat. No. 11,110,119

BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS

Calm Water Therapeutics L...


1. A method for prolonging the stability of an ocular surface tear film of a subject, comprising contacting said ocular surface of said subject with a composition comprising a graft copolymer having a positively charged backbone and one or more hydrophilic water soluble side chains selected from the group consisting of polyethylene glycols, polysaccharides, poly(meth)acrylates, polyacrylamides, polyvinyl alcohol (PVA), polyethyloxazoline, poly-N-vinyl pyrrolidone (NVP) and poly boronic-based polymers, wherein the positively charged backbone is selected from the group consisting of poly(2-vinyl pyridine), poly(4-vinyl pyridine) and vinyl co-polymers thereof, in an amount and for a duration so as to prolong the stability of said tear film of said subject.
US Pat. No. 11,112,693

CURABLE COLORING COMPOSITION, COLOR FILTER, SOLID-STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, AND METHOD FOR PRODUCING CURED FILM

FUJIFILM Corporation, To...


1. A curable coloring composition comprising:a coloring agent including a phthalocyanine pigment having Al as a central metal;
a basic pigment derivative; and
a curable compound,
wherein the coloring agent includes 80% by mass or more of the phthalocyanine pigments, the content of the phthalocyanine pigment having Al as a central metal among phthalocyanine pigments is 30% by mass or more, and the phthalocyanine pigment having Al as a central metal has a ligand including a phosphorus atom.

US Pat. No. 11,109,607

OIL-BASED COMPOSITIONS FOR ENHANCING ORAL HEALTH AND GENERAL WELLNESS IN HUMANS


1. An oil-based mouthwash composition comprising:a glyceride of medium-chain fatty acids, wherein the medium-chain fatty acid comprises about 6 to 12 carbon atoms;
cinnamon bark; and
at least one essential oil selected from the group consisting of cinnamon oil, oregano oil, avocado oil, coconut oil, and apricot oil, and
wherein the mouthwash composition is essentially free of alcohol and water and reduces biofilm in the mouth.

US Pat. No. 11,110,120

COMPOSITIONS COMPRISING CINNAMALDEHYDE AND ZINC AND METHODS OF USING SUCH COMPOSITIONS

Societe des Produits Nest...


1. A method for treating or reducing a risk and/or a severity of high blood pressure, the method comprising administering a food product to a human in need thereof and who is not obese or overweight,the food product comprising cinnamaldehyde and zinc in a cinnamaldehyde:zinc ratio in molarity of 1:0.5 to 1:0.005,
the food product is selected from the group consisting of a beverage, a cereal bar, a dairy bar, a soup, a breakfast cereal, muesli, a candy, a cookie, a biscuit, a cracker, a dairy product, a tablet, a capsule, a pastille and a liquid,
the food product comprising the cinnamaldehyde at a flavoring concentration of from 31.87 ppm to 6191 ppm, and
the food product comprises at least one of zinc chloride, zinc sulfate, zinc lactate or zinc citrate that provides at least a portion of the zinc.

US Pat. No. 11,111,405

LOW VOC AND HIGH SOLID FLUOROPOLYMER FOR COATING APPLICATIONS

HONEYWELL INTERNATIONAL I...


1. A method for reducing the release of volatile organic compounds (VOCs) into the Earth's atmosphere during coating operations of the type which permit the escape of VOCs into the atmosphere, the method comprising:(a) providing a substrate to be coated with a coating composition of the type comprising a carrier comprising volatile organic compounds;
(b) providing a coating composition which is formed by steps comprising:(i) providing one or more fluorocopolymers by copolymerization of (1) a first monomer selected from the group consisting of 1,3,3,3-tetrafluoroolefin (HFO-1234ze), 2,3,3,3-tetrafluoroolefin (HFO-1234yf) and combinations of these, (2) a second monomer comprising vinyl ester(s), and (3) a third monomer comprising vinyl ether(s), wherein at least a portion of said vinyl ether monomer is a hydroxyl group-containing vinyl ether; and
(ii) providing a carrier comprising VOCs for said one or more fluorocopolymers; and
(iii) combining said one or more fluorocopolymers with said carrier such that said one or more fluorocopolymers comprise at least about 70% by weight of said coating composition and the VOCs of said carrier comprise not greater than about 30% by weight of said coating composition;

(c) coating the substrate with said coating composition of said providing step (b); and
(d) forming a protective polymeric layer on and adhered to said substrate by allowing at least a portion of said VOCs in said carrier to evaporate into the atmosphere, whereby said protective coating is formed.

US Pat. No. 11,109,608

COMPOSITION FOR COATING FOOD

CAPOL GMBH, Elmshorn (DE...


1. A composition for coating food, in particular confectionery, jellies, and gummies, comprising:(A): 60 wt. % to 99.94 wt. %, based on a total amount of the composition, of an oil having a content of monounsaturated fatty acids of more than 70 wt. %, based on a total amount of the oil; and
(B): 0.06 wt. % to 0.15 wt. %, based on a total amount of the composition, of ascorbyl palmitate.

US Pat. No. 11,110,122

METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPE

NEW YORK UNIVERSITY, New...


1. A method of inducing a phenotypic change in a population of monocytes and/or macrophages, said method comprising:administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein said carrier molecule is selected from (i) a modified or variant human albumin protein or fragment thereof and (ii) a modified or variant human immunoglobulin G protein or fragment thereof, wherein the carrier molecule is defective in neonatal Fc receptor (FcRn) binding, and wherein said carrier molecule and agent are taken up via macropinocytosis by monocytes and/or macrophages of the population, thereby inducing a phenotypic change in said monocytes and/or macrophages.

US Pat. No. 11,111,407

SEALING RESIN COMPOSITION, ELECTRONIC COMPONENT DEVICE, AND METHOD OF MANUFACTURING ELECTRONIC COMPONENT DEVICE

SHOWA DENKO MATERIALS CO....


1. A sealing resin composition comprising:an epoxy resin (A), a curing agent (B) having at least one amino group in one molecule, and an inorganic filler (C), wherein:
the inorganic filler (C) comprises a first inorganic filler (C1) having an average particle size from 0.1 ?m to 20 ?m and a second inorganic filler (C2) having an average particle size from 10 nm to 80 nm,
a value obtained by multiplying a specific surface area of the inorganic filler (C), by a proportion of a mass of the inorganic filler (C) in a solid mass of the sealing resin composition, is 4.0 m2/g or more, and
the sealing resin composition has a viscosity, at 25° C., from 0.1 Pa·s to 50.0 Pa·s.

US Pat. No. 11,110,123

T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS

Triumvira Immunologics US...


1. A HER2 (Human Epidermal Growth Factor Receptor 2) T cell-antigen coupler (HER2-TAC) polypeptide, comprising the amino acid sequence set forth in SEQ ID NO: 66, SEQ ID NO: 68, or SEQ ID NO: 76.
US Pat. No. 11,111,152

PREPARATION METHOD FOR MODIFIED MOLECULAR SIEVE AND MODIFIED MOLECULAR SIEVE-CONTAINING CATALYTIC CRACKING CATALYST

PETROCHINA COMPANY LIMITE...


1. A preparation method of a modified molecular sieve, wherein the preparation method comprises: mixing a molecular sieve slurry, a compound solution containing Group IIIB metal ion of the periodic table, an organic complexing agent, a dispersant and a precipitating agent to obtain a mixed slurry containing the precipitate of Group IIIB element of the periodic table and the molecular sieve, followed by drying and optionally calcining, to obtain the Group IIIB element-modified molecular sieve, wherein the weight ratio of the Group IIIB element in terms of oxide to the molecular sieve on dry basis is 0.3 to 10: 100, the molar ratio of the organic complexing agent to the Group IIIB metal ion is 0.3 to 10: 1, and the molar ratio of the dispersant to the Group IIIB metal ion is 0.2 to 16: 1; wherein the mixing of the molecular sieve slurry, the compound solution containing the Group IIIB metal ion of the periodic table, the organic complexing agent, the dispersant and the precipitating agent is carried out by uniformly mixing the compound solution containing the Group IIIB metal ion of the periodic table, the organic complexing agent, the dispersant with the molecular sieve slurry, adding the precipitating agent and stirring for at least 10 minutes.
US Pat. No. 11,111,408

POLYESTER RESIN, WATER DISPERSION OF POLYESTER RESIN AND METHOD FOR PREPARING WATER DISPERSION

TOYOBO CO., LTD., Osaka ...


1. A polyester resin represented by the following chemical structure of formula (I) and having an acid value of 250 to 2,500 eq/106 g and a number-average molecular weight of 2,000 to 50,000:(X—O)r—W—(O—(CO—Z—CO—O—Y—O)p—X)q ??(I)
wherein W is a residue of a polyhydric alcohol having hydroxyl groups in numbers of (q+r);
(CO—Z—CO—O—Y—O) is a skeleton of polyester resin prepared by polymerization using a polyvalent carboxylic acid ingredient Z and a polyhydric alcohol ingredient Y as polymerizing ingredients;
X is a residue of polybasic acid having two or more carboxyl groups or is hydrogen (except the case wherein all of X in numbers of (q+r) are hydrogen);
X, Y and Z each may be the same as or different from each other and, even in the same repetitive unit, X, Y and Z each may be the same as or different from each other;
average value of p is 3 or more, average value of q is more than 0 and is 15 or less, average value of r is 0 or more and is less than 15, and (q+r) is 3 or more and 15 or less; and
wherein the ratio of the carboxyl group equivalent derived from X and the equivalent of W is 3.39 to 12.57.

US Pat. No. 11,109,611

COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL


1. A pet food composition comprising:protein, carbohydrates, fat, fiber, and
at least 6 distinct metabolites for individually modulating organic matter digestibility, dry matter digestibility, fiber digestibility, energy digestibility, fat digestibility and protein digestibility in a companion animal, the at least 6 distinct metabolites comprising at least one of trigonelline (N?-methylnicotinate), mannose, arachidonate (20:4n6), betaine, dihomo-linoleate (20:2n6), or 1-heptadecanoylglycerophosphoethanolamine;
wherein the metabolite that modulates organic matter digestibility is selected from the group consisting of trigonelline (N?-methylnicotinate), mannose, arachidonate (20:4n6), dihomo-linoleate (20:2n6), docosapentaenoate (n6 DPA; 22:5n6), pantothenate, X-09789, dihomo-linolenate (20:3n3), dihomo-linolenate (20:3n6), 3-hydroxybutyrate (BHBA), adrenate (22:4n6), docosapentaenoate (n3 DPA; 22:5n3), eicosenoate (20:1n9), eicosenoate (20:1n11), X-11378, alpha linolenate (18:3n3), gamma linolenate (18:3n6), stachydrine, glycerate, gamma-glutamylphenylalanine, X-16975, X-17185, arabitol, creatine, octanoylcarnitine, trans-4-hydroxyproline, X-17010, glycolate (hydroxyacetate), N-acetylornithine, campesterol, oxidized glutathione (GSSG), phenylalanine, oleoyltaurine, arabonate, X-12450, palmitoleate (16:1n7), acetylcarnitine, palmitate (16:0), erythritol, linoleate (18:2n6), stearate (18:0), and mixtures thereof;
wherein the metabolite that modulates dry matter digestibility is selected from the group consisting of mannose, trigonelline (N?-methylnicotinate), arachidonate (20:4n6), dihomo-linoleate (20:2n6), N-palmitoyl taurine, docosapentaenoate (n6 DPA; 22:5n6), X-09789, pantothenate, docosapentaenoate (n3 DPA; 22:5n3), X-16975, 3-hydroxybutyrate (BHBA), X-11378, linolenate [alpha or gamma; (18:3n3 or 6)], gamma-glutamylphenylalanine, dihomo-linolenate (20:3n3 or n6), eicosenoate (20:1n9 or 11), arabitol, adrenate (22:4n6), X-17185, Glycerate, glutathione (oxidized (GSSG)), mannitol, octanoylcarnitine, N-acetylornithine, X-17010, glycolate (hydroxyacetate), stachydrine, campesterol, palmitoleate (16:1n7), creatine, X-12450, oleoyltaurine, arabonate, trans-4-hydroxyproline, phenylalanine, erythritol, palmitate (16:0), and mixtures thereof;
wherein the metabolite that modulates energy digestibility is selected from the group consisting of trigonelline (N?-methylnicotinate), mannose, arachidonate (20:4n6), dihomo-linoleate (20:2n6), docosapentaenoate (n6 DPA; 22:5n6), N-palmitoyl taurine, betaine, X-09789, pantothenate, adrenate (22:4n6), dihomo-linolenate (20:3n3), dihomo-linolenate (20:3n6), X-11378, glycerate, 3-hydroxybutyrate (BHBA), docosapentaenoate (n3 DPA; 22:5n3), stachydrine, X-17185, eicosenoate (20:1n9), eicosenoate (20:1n11), alpha linolenate (18:3n3), gamma linolenate (18:3n6), gamma-glutamylphenylalanine, X-16975, creatine, campesterol, glycolate (hydroxyacetate), X-17010, octanoylcarnitine, N-acetylornithine, trans-4-hydroxyproline, phenylalanine, oxidized glutathione (GSSG), arabitol, mannitol, acetylcarnitine, erythritol, oleoyltaurine, X-12450, palmitoleate (16:1n7), arabonate, palmitate (16:0), docosahexaenoate (DHA; 22:6n3), linoleate (18:2n6), stearate (18:0), and mixtures thereof;
wherein the metabolite that modulates fat digestibility is selected from the group consisting of trigonelline (N?-methylnicotinate), X-09789, arachidonate (20:4n6), mannose, betaine, oxidized glutathione (GSSG), X-11378, dihomo-linoleate (20:2n6), glycerate, campesterol, docosapentaenoate (n6 DPA; 22:5n6), glycolate (hydroxyacetate), pantothenate, adrenate (22:4n6), X-17185, N-acetylornithine, gamma-glutamylphenylalanine, octanoylcarnitine, stachydrine, dihomo-linolenate (20:3n3), dihomo-linolenate (20:3n6), docosapentaenoate (n3 DPA; 22:5n3), 3-hydroxybutyrate (BHBA), X-17010, X-16975, 15-methylpalmitate (isobar with 2-methylpalmitate), mannitol, citrulline, alpha linolenate (18:3n3), gamma linolenate (18:3n6), phenylalanine, erythritol, arabitol, eicosenoate (20:1n9), eicosenoate (20:1n11), cholate, gamma-glutamylalanine, creatine, 3-dehydrocholate, docosahexaenoate (DHA; 22:6n3), trans-4-hydroxyproline, 7-ketodeoxycholate, 12-dehydrocholate, chenodeoxycholate, acetylcarnitine, palmitoleate (16:1n7), and mixtures thereof;
wherein the metabolite that modulates protein digestibility is selected from the group consisting of trigonelline (N?-methylnicotinate), X-09789, mannose, dihomo-linoleate (20:2n6), docosapentaenoate (n6 DPA; 22:5n6), X-11378, trans-4-hydroxyproline, arachidonate (20:4n6), X-17185, betaine, X-15461, N-acetylornithine, creatine, stachydrine, 4-hydroxyphenylacetate, eicosenoate (20:1n9), eicosenoate (20:1n11), campesterol, gamma-glutamylphenylalanine, pantothenate, mannitol, docosapentaenoate (n3 DPA; 22:5n3), adrenate (22:4n6), alpha linolenate (18:3n3), gamma linolenate (18:3n6), X-16975, glycerate, phenylalanine, oxidized glutathione (GSSG), palmitoleate (16:1n7), octanoylcarnitine, X-12450, erythritol, 3-hydroxybutyrate (BHBA), 3-(4-hydroxyphenyl)propionate, 1-heptadecanoylglycerophosphocholine, 3-phenylpropionate (hydrocinnamate), oleoyltaurine, and mixtures thereof;
wherein the metabolite that modulates fiber digestibility is selected from the group consisting of 1-heptadecanoylglycerophosphoethanolamine, 1-palmitoylplasmenylethanolamine, 1-palmitoylglycerol (1-monopalmitin), alpha-tocopherol, ribitol, and mixtures thereof;
wherein the at least 6 distinct metabolites comprise at least two of trigonelline (N?-methylnicotinate), mannose, arachidonate (20:4n6), betaine, dihomo-linoleate (20:2n6), or 1-heptadecanoylglycerophosphoethanolamine; and
wherein the pet food composition provides at least a 5% increase or at least a 5% decrease in at least one of organic matter digestibility, dry matter digestibility, fiber digestibility, energy digestibility, fat digestibility or protein digestibility in the companion animal upon administration of the pet food composition to the companion animal.

US Pat. No. 11,110,124

CELL DERIVED EXTRACELLULAR VESICLES FOR THE TREATMENT OF DISEASES

RHEINISCHE FRIEDRICH-WILH...


1. A method for the production of extracellular vesicles, the method comprising the steps of(a) Culturing a tumor cell, an epithelial cell, or a fibroblast,
(b) Bringing into contact the tumor cell, the epithelial cell, or the fibroblast with at least one ligand of an innate immunity receptor in an amount and time sufficient for the tumor cell, the epithelial cell, or the fibroblast to release extracellular vesicles with an anti-infective and/or anti-tumor activity and/or immune stimulatory activity,
(c) Isolating and/or purifying the released extracellular vesicles.

US Pat. No. 11,110,639

METAL DETECTABLE POLYURETHANE FILM


1. A method for manufacturing a metal detectable polyurethane film, the method comprising:compounding polyurethane and metallic particles in a compounder to pelletize the resin and the metallic particles as polyurethane pellets;
blending and heating a ratio of the polyurethane pellets and additives in a batch blender for a selected period to form a blended mixture liquid film, the additives in the blended mixture liquid film being selected from the group consisting of resins, barium lubricants, pigments, chromium, silicon, carbon, titanium, calcium, and colorants;
vacuum loading the blended mixture liquid film into a drying hopper;
dehumidifying the blended mixture liquid film in the drying hopper at an elevated temperature to reach a selected dew point; and
extruding the blended mixture liquid film through an extruder.

US Pat. No. 11,111,153

PROCESS FOR MAKING MOLECULAR SIEVES

ExxonMobil Research and E...


1. A process of preparing crystals of a molecular sieve, the process comprising the steps of:a. combining at least a source of a tetravalent element X, a morphology modifier L, and water to form a synthesis mixture;
b. heating said synthesis mixture under crystallization conditions for a time of about 1 hour to 100 days to form the crystals of the molecular sieve; and
c. recovering said crystals of the molecular sieve from the synthesis mixture;
wherein the morphology modifier L is selected from the group consisting of cationic surfactants having a single quaternary ammonium group comprising at least one hydrocarbyl group having at least 12 carbon atoms, and is present in the synthesis mixture before nucleation or crystallization of the crystals begins;
wherein if the molecular sieve is one which requires a structure directing agent Q, the morphology modifier L is different from and is present in addition to the structure directing agent Q;
wherein the molar ratio L:X in the synthesis mixture is in the range of from 0.0001 to 0.03; and
wherein the synthesis mixture is a liquid that is substantially a single phase, or a mixture of solid and a liquid that is substantially a single phase is substantially a single phase;
and wherein the molecular sieve has a framework structure selected from the group consisting of MRE, MWW, MTW, FAU, EMT, MFS, MEI, BEA and its polymorphs, TON and MTT.

US Pat. No. 11,111,409

COATING COMPOSITION COMPRISING SELF-CROSSLINKABLE CORE-SHELL PARTICLES AND IMPARTING IMPROVED STAIN RESISTANCE

PPG Industries Ohio, Inc....


1. A coating composition comprising:an aqueous dispersion of self-crosslinkable core-shell particles, wherein the core-shell particles comprise (1) a polymeric core at least partially encapsulated by (2) a polymeric shell comprising urethane linkages, keto and/or aldo functional groups, and hydrazide functional groups, wherein the polymeric core is covalently bonded to at least a portion of the polymeric shell, and
a hydrophobic additive comprising a wax and/or a silicon-containing compound, wherein the hydrophobic additive is non-reactive with the polymeric core and the polymeric shell.

US Pat. No. 11,110,125

COORDINATING GENE EXPRESSION USING RNA DESTABILIZING ELEMENTS

Chimera Bioengineering, I...


1. A method of expressing a plurality of transgenes, comprising the steps of: obtaining a primary T-cell comprising a receptor, a first heterologous nucleic acid comprising a polynucleotide encoding a first transgene, and a polynucleotide encoding a first RNA destabilizing element (RDE), wherein the first RDE is an AU rich element, a second heterologous nucleic acid comprising a polynucleotide encoding a second transgene, and a polynucleotide encoding a second RDE, wherein the second RDE is an AU rich element, wherein the first heterologous nucleic acid is transcribed to make a first transcript encoding the first transgene operably linked to the first RDE, wherein a glycolytic enzyme with RDE binding activity-binds to the first RDE and regulates expression of the first transgene, and the second heterologous nucleic acid is transcribed to make a second transcript encoding the second transgene operably linked to the second RDE, wherein the glycolytic enzyme with RDE binding activity-binds to the second RDE and regulates expression of the second transgene;and binding the receptor on the primary T-cell to a ligand wherein binding of the ligand by the receptor activates the primary T-cell and the primary T-cell increases glycolytic activity whereby the glycolytic enzyme with RDE binding activity catalyzes a step of glycolysis, wherein activation of glycolysis in the primary T-cell reduces the amount of the glycolytic enzyme with RDE binding activity available to bind the first RDE and reduces the amount of the glycolytic enzyme with RDE binding activity available to bind the second RDE which produces increased expression of the first and second transgenes.

US Pat. No. 11,111,154

AQUEOUS MISCIBLE ORGANIC-LAYERED DOUBLE HYDROXIDE

SCG CHEMICALS CO., LTD.


1. A layered double hydroxide of the formula:[Mz+1-xM?y+x(OH)2]a+(Xn?)a/r?bH2O?c(Y)
wherein M and M? are metal cations, z=1 or 2; y=3 or 4, x is 0.1 to 1, b is 0 to 10, X is an anion, r is 1 to 3, n is the charge on the anion X, a=z(1-x)+xy-2, c is greater than 0 to 10, and Y is an aqueous miscible organic solvent; and
wherein the layered double hydroxide exhibits a BET pore volume (N2) of at least 1 cm3/g and one or more of:a specific surface area greater than 150 m2/g;
a loose bulk density of less than 0.28 g/mL;
a tap density of 0.35 g/mL;
a first minima of a derivative of weight loss as a function of temperature in a thermogravimetric analysis that is 150° C. to 191° C.; or
a second minima of a derivative of weight loss as a function of temperature in a thermogravimetric analysis that is 340° C. to 392° C.


US Pat. No. 11,111,410

DUAL CURE SOFT TOUCH COATINGS

Arkema France, Colombes ...


1. A coating composition comprised of at least one free radical-curable ethylenically unsaturated compound, at least one polyol and at least one polyisocyanate, wherein the at least one free radical-curable ethylenically unsaturated compound includes at least one isocyanurate tri(meth)acrylate or derivative thereof or at least one isocyanate functionality-containing urethane (meth)acrylate and the weight ratio of (polyol+polyisocyanate): free radical-curable ethylenically unsaturated compound is from 1:1 to 10:1.
US Pat. No. 11,109,613

RECIPE FOR VEGETABLE GNOCCHI AND THE PRODUCTION PROCESS THEREOF

BOCON S.R.I., Pieve di S...


1. A composition for producing vegetable gnocchi the vegetable gnocchi being produced having a water content of between 70% and 80% by weight of the total weight of the vegetable gnocchi, the composition comprising, as a percentage of the total weight of the ingredients of the composition;40% to 90% of a fiber-rich vegetable pure, wherein potatoes are excluded from vegetables that are reduced to make the fiber-rich vegetable purée; and
10% to 60% of grain and non grain gluten-free flour; wherein
the composition is free of gluten, egg proteins and milk proteins.

US Pat. No. 11,110,126

METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING

Korea University Research...


1. A method of enhancing NK cell expansion, comprising:treating natural killer (NK) cells with a p53 inhibitor; or a reactive oxygen species (ROS) inhibitor and a p53 inhibitor, wherein the p53 inhibitor is one or more selected from the group consisting of 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone hydrobromide (pifithrin-?) and pifithrin-?.

US Pat. No. 11,111,411

LIGHT COLOR ROSIN ESTER COMPOSITIONS AND METHODS OF MAKING SAME

Kraton Polymers LLC, Hou...


1. A rosin ester composition comprisinga reaction product of one or more rosins, one or more polyhydric alcohols, and optionally one or more monocarboxylic acids, and optionally one or more polycarboxylic acids having from 2 to 54 carbon atoms;
from 5 ppm to 200 ppm of a co-catalyst, and
optionally, a disproportionation catalyst, an esterification catalyst, or combinations thereof;
wherein the co-catalyst has a triplet formation quantum yield (?T) of greater than 0.5 and a triplet lifetime (?T) of greater than 0.5 microseconds.

US Pat. No. 11,110,127

USE OF NANOPARTICLES COATED WITH RED BLOOD CELL MEMBRANES TO TREAT HEMOLYTIC DISEASES AND DISORDERS

CELLICS THERAPEUTICS, INC...


1. A method for reducing antibody attack in a mammal, which method comprises administering, to a mammal in need of the reduction, an effective amount of a nanoparticle comprising a) an inner core comprising a material selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid, and b) an outer surface comprising a plasma membrane derived from a red blood cell, wherein:said mammal is a pregnant mammal and said pregnant mammal's antibody attacks her fetus' red blood cells, or said mammal is a baby and said baby's red blood cells are attacked by an antibody of said baby's mother, and said pregnant mammal's antibody or said mother's antibody is an anti-A, anti-B, anti-rhesus D, anti-rhesus E, anti-rhesus c, anti-rhesus e, anti-rhesus C, anti-Kell, anti-Lewis, anti-Duffy, anti-Kidd, anti-P, anti-MN, or combinations thereof.

US Pat. No. 11,111,156

PROCESS FOR THE PRODUCTION OF HIGH PURITY IRIDIUM(III)CHLORIDE HYDRATE


1. A process for the production of high purity iridium(III) chloride hydrate having the formula IrCl3·×H2O·yHCl, wherein x=1.5 to 5 and y=0 to 1, the process comprising:(1) providing at least one material selected from the group consisting of solid H2[IrC16] hydrate, aqueous, at least 1 wt. % H2[IrCl6] solution, and solid IrCl4 hydrate;
(2) adding, to the at least one material provided in step (1), at least one monohydroxy compound selected from the group consisting of monohydroxy compounds that are miscible with water at any ratio, primary monoalcohols comprising 4 to 6 carbon atoms, and secondary monoalcohols comprising 4 to 6 carbon atoms at a molar ratio of Ir(IV): monohydroxy compound from 1: 0.6 to 1_1000, and allowing to react for 0.2 to 48 hours in a temperature range from 20 to 120° C., followed by removing volatile components from the reaction mixture thus formed.

US Pat. No. 11,110,128

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

RegenLab USA LLC, New Yo...


1. A sterilized, vacuum-sealed separator tube for preparing a platelet concentrate from whole blood comprising:An inlet adapted to introduce whole blood;
An anticoagulant;
A non-toxic and non-mutagenic thixotropic gel; and
wherein, when the separator tube is at least partially filled with the whole blood and centrifuged at a force of about 1,500 g up to about 2,000 g for about 3 to about 10 minutes once in a single centrifugation, blood components in the whole blood are separated into a platelet concentrate to be administered without supernatant removal to a patient, and red blood cells, wherein the platelet concentrate contains greater than 400 billion platelets per liter,
wherein the thixotropic gel forms a barrier between the platelet concentrate and red blood cells.

US Pat. No. 11,111,413

CHEMICAL-MECHANICAL POLISHING SOLUTION HAVING HIGH SILICON NITRIDE SELECTIVITY

ANJI MICROELECTRONICS TEC...


1. A chemical-mechanical polishing slurry consisting of silica particles, a compound containing one or more carboxyl groups, a pH adjustor, and water, wherein the compound containing one or more carboxyl groups is selected from the group consisting of a pyridine compound, a piperidine compound, a pyrrolidine compound, a pyrrole compound, and any derivative and/or combination thereof.
US Pat. No. 11,110,129

METHOD FOR TREATING MULTIPLE SCLEROSIS

China Medical University,...


1. A method for treating a multiple sclerosis, the method comprising administering a composition containing a plurality of insulin-like growth factor 1 receptor positive umbilical cord mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, wherein each of the umbilical cord mesenchymal stem cells is derived from Wharton's jellies and isolated by using an insulin-like growth factor 1 receptor antibody and then cultured in a medium containing platelet-derived growth factor BB (PDGF-BB) at 2.5-50 ng/mL to enhance the expression of insulin-like growth factor 1 receptors in the umbilical cord mesenchymal stem cells, wherein the composition is administered by an intravenous injection.
US Pat. No. 11,111,414

POLISHING COMPOSITION

FUJIMI INCORPORATED, Kiy...


1. A polishing composition having a pH of less than 7, consisting of an abrasive grain, an amide compound, a dispersing medium or solvent, and a pH adjusting agent, wherein the amide compound has a group forming a ? conjugated system with a carbonyl group.
US Pat. No. 11,109,617

REDUCING LEVELS OF NICOTINE IN PLANTS

22nd Century Limited, LLC...


1. A tobacco plant comprising plant cells with one or more mutations introduced into their genomes in a region with a polynucleotide sequence that hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO: 3, wherein the plant exhibits reduced nicotine levels as compared to a control tobacco plant.
US Pat. No. 11,110,130

PHARMACEUTICAL CARRIERS CONTAINING MIRNAS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES CAUSED BY HYPERGLYCEMIA

UNICYTE EV AG, Oberdorf ...


1. A method for treatment of a fibrotic disease caused by hyperglycaemia found in diabetic patients comprising administering to a patient in need thereof a pharmaceutically acceptable carrier carrying microRNA miR222.
US Pat. No. 11,111,415

CHEMICAL MECHANICAL PLANARIZATION OF FILMS COMPRISING ELEMENTAL SILICON

Versum Materials US, LLC,...


1. A polishing method for chemical mechanical planarization of a semiconductor substrate comprising at least one surface containing elemental silicon, comprising the steps of: contacting the at least one surface containing elemental silicon with a polishing pad; delivering a polishing composition to the at least one surface containing elemental silicon; wherein the polishing composition consisting essentially of: abrasive particles ranging from 0.01 wt. % to 15 wt. %; a compound to enhance removal rate of films comprising elemental silicon ranging from 0.001 wt. % to 0.5 wt. %; liquid carrier; and optionally an additive selected from the group consisting of (i) a polyacrylic acid or its salts with molecular weight ranging between 500 and 100,000; (ii) an additive having a functional group selected from the group consisting of organic carboxylic acids and salts thereof, amino acids and salts thereof, aminocarboxylic acids and salts thereof, N-acylamino acids and salts thereof, organic sulfonic acids and salts thereof, organic phosphonic acids and salts thereof, polymeric carboxylic acids and salts thereof, polymeric sulfonic acids and salts thereof, polymeric phosphonic acids and salts thereof, arylamines, aminoalcohols, aliphatic amines, heterocyclic amines, hydroxamic acids, substituted phenols, sulfonamides, thiols, polyols having hydroxyl groups, and combinations thereof; and combinations of (i) and (ii); a pH adjusting agent; a surfactant selected from the group consisting of a) non-ionic surface wetting agents; b) anionic surface wetting agents; c) cationic surface wetting agents; d) ampholytic surface wetting agents; and mixtures thereof; and a biological growth inhibitors or preservatives to prevent bacterial and fungal growth during storage; wherein pH of the polishing composition is between 2 and 12; wherein the abrasive particles are selected from the group consisting of fumed silica, colloidal silica, fumed alumina, colloidal alumina, cerium oxide, ceria-silica composite particles, titanium dioxide, zirconium oxide, polystyrene, polymethyl methacrylate, mica, hydrated aluminum silicate, and combinations thereof; and wherein the compound to enhance removal rate of films comprising elemental silicon is selected from the group consisting of isothiazolinone and derivatives, thiazolinone and derivatives, imidazolidine and derivatives, pyrozolidine and derivatives, imidazole and derivatives, pyrazole and derivatives, thiazole and derivatives, isothiazole, and derivatives, thiazolidine and derivatives, isothiazolidine and derivatives, dithiolane and derivatives, triazole and derivatives, tetrazole and derivatives, thiadiazole and derivatives, acetone, benzophenone, acetophenone, acetylacetone, butanol, 3-hydroxybutanal, p-nitrobenzenzaaldehyde, cinnamaldehyde, vanillin, and combinations thereof; and polishing the at least one surface containing elemental silicon with the polishing composition.
US Pat. No. 11,110,131

METHODS AND MATERIALS FOR TREATING LUNG DISORDERS


1. A composition comprising:a dried amnion tissue preparation lacking viable cells;
a dried stem cell preparation lacking viable cells, wherein the dried stem cell preparation is a dried umbilical cord-, fat tissue-, or bone marrow-derived stem cell preparation of cellular remnants from lysed stem cells; and
wherein the composition is an inhalable formulation.

US Pat. No. 11,111,416

ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS


1. An anaerobically curable composition comprising:(a) at least one (meth)acrylate component;
(b) an anaerobic cure inducing component; and
(c) a toughening agent selected from the group consisting of: (i) a combination of a styrene butadiene block copolymer and methacrylate functionalised polybutadiene; and (ii) a combination of a styrene butadiene block copolymer, methacrylate functionalised polybutadiene and propoxylated bisphenol A fumarate polyester; wherein the composition will not cure until exposed to an anaerobic environment and wherein the toughening agent is a combination of a styrene butadiene block copolymer and methacrylate functionalised polybutadiene and the methacrylate functionalised polybutadiene is present in an amount of about 5 to about 20 wt %.

US Pat. No. 11,110,132

LIVE ATTENUATED PARASITIC VACCINE

Ohio State Innovation Fou...


1. An avirulent live vaccine, comprising a recombinant protozoan from the order Trypanosomatida having a knocked out or silenced cyclophilin 19 (cyp19) gene.
US Pat. No. 11,110,133

LYOPHILIZED COMPOSITION FOR PRESERVING MICROBIOTA IN ITS ECOSYSTEM

UNIVERSITE PARIS DESCARTE...


1. A lyophilized composition comprising a collected microbiota and a mixture of cryoprotectants,wherein said mixture of cryoprotectants comprises maltodextrin and trehalose in a maltodextrin/trehalose (M/T) weight ratio ranging from 35/65 to 45/55,
wherein said microbiota is faecal microbiota contained in stool, and
wherein said lyophilized composition comprises at least one viable bacterial population that show extreme oxygen sensitivity (EOS) after at least 6 months of storage and wherein said microbiota is unchanged compared with the microbiota existing naturally in the body and further comprises at least bacterial metabolites.

US Pat. No. 11,110,134

DIRECT-FED MICROBIALS

Microbial Discovery Group...


1. A nutrient composition comprising an isolated Bacillus strain selected from the group consisting of Bacillus strain 101 (NRRL No. B-67218), Bacillus strain 235 (NRRL No. B-67219), Bacillus strain 77 (NRRL No. B-67274), Bacillus strain 177 (NRRL No. B-67275), Bacillus strain 102 (NRRL No. B-67276), a strain having all of the identifying characteristics of Bacillus strain 101 (NRRL No. B-67218), a strain having all of the identifying characteristics of Bacillus strain 235 (NRRL No. B-67219), a strain having all of the identifying characteristics of Bacillus strain 77 (NRRL No. B-67274), a strain having all of the identifying characteristics of Bacillus strain 177 (NRRL No. B-67275), a strain having all of the identifying characteristics of Bacillus strain 102 (NRRL No. B-67276), and combinations thereof, wherein the strain(s) are in a form selected from the group consisting of a pellet, a gel, a freeze-dried composition, a top-dressing, a liquid, and a dried powder.
US Pat. No. 11,110,649

ADDITIVELY MANUFACTURED PRODUCTS HAVING A MATTE SURFACE FINISH

Carbon, Inc., Redwood Ci...


1. A method of making an object having a matte surface finish by stereolithography, comprising the steps of:(a) stereolithographically producing an intermediate object by polymerization of a dual cure resin with a first light having a first peak wavelength, the object having excess unpolymerized resin retained on the surface thereof;
(b) separating a portion of said excess unpolymerized resin from said object while leaving a thin film of unpolymerized resin on the surface thereof;
(c) partially curing said thin film by exposing said thin film to a second light at a second peak wavelength; and then
(d) further curing said intermediate object by heating, microwave irradiating, or both heating and microwave irradiating, to produce an object having a matte surface finish.

US Pat. No. 11,111,419

PHOTOCROSSLINKABLE TRANSPARENT ADHESIVE MATERIAL, TRANSPARENT ADHESIVE MATERIAL LAYERED BODY, AND LAYERED BODY FOR CONSTITUTING OPTICAL DEVICE

Mitsubishi Chemical Corpo...


1. A photocrosslinkable transparent adhesive material comprising:an outermost surface layer comprising an acrylic polymer (B) and a photocrosslinking initiator; and
an intermediate layer comprising an olefinic polymer (A), a crosslinking agent, and a photocrosslinking initiator,
wherein the intermediate layer comprises the crosslinking agent within a range of 1 to 50 parts by mass relative to 100 parts by mass of the olefinic polymer, and a (meth)acrylate monomer as the crosslinking agent.

US Pat. No. 11,110,135

BACTERIAL STRAINS BELONGING TO THE GENUS BIFIDOBACTERIUM FOR USE IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA

PROBIOTICAL S.P.A., Nova...


1. A medicament comprising a bacterial composition comprising:at least one bacterial strain belonging to the species Bifidobacterium bifidum capable of absorbing cholesterol onto its surface cell wall selected from the group consisting of the bacterial strain B. bifidum BB06 (MB107) DSM 24688 and the bacterial strain B. bifidum MB109 DSM 23731, and
at least one bacterial strain belonging to the species Bifidobacterium lactis, Bifidobacterium breve or Bifidobacterium infantis capable of hydrolyzing bile salts on an intracellular and/or extracellular level,
the bacterial composition in an effective amount for preventive or curative treatment of hypercholesterolaemia in a subject.

US Pat. No. 11,111,420

WATERBORNE BONDING ADHESIVE FORMULATION FOR SHEET MEMBRANE INCORPORATING A SOLID PLASTICIZER

ILLINOIS TOOL WORKS INC.,...


1. A method of bonding a sheet membrane to an exterior substrate comprising:applying an adhesive formulation to at least one of the sheet membrane or the exterior substrate while said adhesive formulation is wet, said adhesive formulation comprising:
a polyurethane dispersion (PUD);
(vinyl acetate/ethylene) copolymer (VAE);
an alkanolamine;
a tackifying resin;
an ether; and
water, wherein the formulation has a pH of from 7.0 to 12.5; and
bringing the sheet membrane and the exterior substrate into contact with said adhesive formulation therebetween during construction outdoors, while said adhesive formulation is wet, to bond simultaneously to the sheet membrane and the exterior substrate upon cure of said adhesive formulation, wherein said adhesive formulation builds strength as the water evaporates thereby facilitating adhesion of the sheet membrane to the exterior substrate, the exterior substrate being steel, wood, concrete, a roof board, insulation, or a fiberglass mat roof board.

US Pat. No. 11,112,709

TONER AND TONER MANUFACTURING METHOD

CANON KABUSHIKI KAISHA, ...


1. A toner, comprising:a toner particle containing a binder resin, the binder resin containing a crystalline resin consisting of a polymer A having a first, second and third monomer units respectively derived from a first, second and third monomer units that are mutually different from each other, wherein
a content of the first monomer unit in the polymer A is 5.0 to 60.0 mol % of the total moles of all monomer units in the polymer A,
a content of the second monomer unit in the polymer A is 20.0 to 95.0 mol % of the total moles of all monomer units in the polymer A,
a storage elastic modulus Gt? (150) of the toner at 150° C. is at least 1.0×104 Pa,
3.00?(SP21?SP11)?25.00 when SP11 (J/cm3)0.5 is the SP value of the first monomer unit, and SP21 (J/cm3)0.5 is the SP value of the second monomer unit,
the crystalline resin consisting of polymer A is the only crystalline resin contained in the binder resin,
the first polymerizable monomer being at least one selected from the group consisting of (meth)acrylic acid esters having a C18-36 alkyl group, and
the third polymerizable monomer is at least one selected from the group consisting of styrene, methyl methacrylate and methyl acrylate.

US Pat. No. 11,110,136

COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF RECURRENT CYSTITIS

PROBIOTICAL S.P.A., Nova...


1. A method to treat bacterial infections caused by E. coli and/or related inflammations of the urinary tract and/or bladder in a subject, the method comprising:administering to the subject an effective amount of a composition comprisinga mixture of bacteria, which comprises:at least a strain of bacteria selected from the group consisting of the strain Lactobacillus plantarum LMG P-21021 (LP01) and the strain Lactobacillus plantarum LMG P-21020 (LP02); and
the strain Lactobacillus paracasei DSM 24243 (LPC09);

a cranberry extract; and
D-mannose.


US Pat. No. 11,110,393

ENHANCED INJECTION OF MERCURY OXIDANTS

ECOLAB USA INC., St. Pau...


1. A method of treating a gas stream containing mercury, comprising:injecting a composition into the gas stream before passing the gas stream into a gas scrubber, wherein the composition consists of an absorbent and a carrying agent; and
vaporizing the carrying agent in the composition after injecting the composition into the gas stream;
wherein the absorbent is selected from the group consisting of copper sulfate, polysulfide, and a mixture of copper sulfate and polysulfide; and
wherein the absorbent does not comprise a halogen oxidant or silica.

US Pat. No. 11,111,421

THERMAL- AND UV-CURING ADHESIVE COMPOSITION


1. A thermal- and UV-curing adhesive composition, comprising:(a) an epoxy (meth)acrylate resin;
(b) a (meth)acrylic acid ester whose homopolymer has a Tg of 60° C. or more;
(c) a heat-curing agent; and
(d) a photopolymerization initiator,
wherein the epoxy (meth)acrylate resin (a) comprises 20% by weight or more of a (meth)acryloyl group based on the total weight of the resin, and
the weight ratio of the epoxy (meth)acrylate resin (a) to the (meth)acrylic acid ester (b) ((a)/(b)) is from 30/70 to 70/30.

US Pat. No. 11,112,710

TONER AND METHOD FOR PRODUCING TONER

CANON KABUSHIKI KAISHA, ...


1. A toner, comprising:a toner particle comprising a binder resin and a polyvalent metal element;
an external additive comprising a spherical silica particle having a number average particle diameter of 20-40 nm and a circularity of 0.80 or more; and
a surface of the toner particle comprising a polyester resin, wherein
0.025×108?(1/A)×B?4.500×108 where A (?·m) is an electrical resistivity of the polyvalent metal element at 20° C., and B (?mol/g) is an amount of the polyvalent metal element in the toner particle.

US Pat. No. 11,110,137

COMBINATION THERAPY FOR TREATMENT OF BRAIN CANCERS

DNATRIX, INC., Houston, ...


1. A method of treating a subject having brain tumor comprising:(a) administering an oncolytic adenovirus to said subject;
(b) administering an anti-PD-1 antibody to said subject; and
(c) assessing tumor response by measuring tumor size;
wherein the oncolytic adenovirus is an adenovirus serotype 5 strain, is selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, contains a deletion of the 24 nucleotides encoding amino acids 122 to 129 of the adenoviral E1A protein, and/or contains an integrin binding RGD-4C motif; and
wherein the anti-PD-1 antibody is pembrolizumab administered at 200 mg per dose; and
wherein the tumor exhibits reduced growth, no growth, a 10% reduction in tumor mass, a 20% reduction in tumor mass, a 30% reduction in tumor mass, a 40% reduction in tumor mass, a 50% reduction in tumor mass, a 60% reduction in tumor mass, a 70% reduction in tumor mass, an 80% reduction in tumor mass, a 90% reduction in tumor mass, or a 100% reduction in tumor mass following initiation of treatment.

US Pat. No. 11,111,422

HYDRAULIC FLUID AND FUEL RESISTANT SEALANTS

PRC-DeSoto International,...


1. A composition comprising:(a) from 35 wt % to 65 wt % of a thiol-terminated sulfur-containing prepolymer;
(b) from 10 wt % to 35 wt % of an organic filler;
(c) from 5 wt % to 30 wt % of an inorganic filler; and
(d) from 5 wt % to 20 wt % of a polyepoxide,
wherein the composition has a specific gravity less than 1.2, wherein specific gravity is determined according to ISO 2781; and
wherein wt % is based on the total weight of the composition.

US Pat. No. 11,112,711

WHITE TONER

CANON KABUSHIKI KAISHA, ...


1. A white toner comprising a toner particle whereinthe toner particle includes a binder resin and a calcium titanate particle,
the binder resin has an acid value, and
a content of the calcium titanate particle in the toner is in the range of from 25 mass % to 80 mass %.

US Pat. No. 11,110,138

NON-REPLICATING VIRUS-DERIVED PARTICLES AND USES THEREOF

CELVERUM INC., Ottawa (C...


1. A composition comprising a non-replicating, cell-internalizing Rhabdovirus-derived particle, wherein said Rhabdovirus-derived particle exhibits RNA which is cross-linked or cleaved into at least two discontinuous RNA polynucleotide sequences, and wherein the composition is produced from a 50 ?l sample of 1×1010 plaque forming units per ml (PFU/ml) live Rhabdovirus subjected to a UV dose of 250 mJ/cm2 for about 40 seconds, the composition inducing less than 40% viability of immortalized cells and about 80% viability of normal non-cancer cells in an in-vitro cytotoxicity assay using a multiplicity of infection of 100 particles per cell.
US Pat. No. 11,111,423

THERMALLY VULCANIZABLE ADHESIVE TAPE WITH SHEAR STRENGTH DURING THE HEATING AND CURING PHASE

TESA SE, Norderstedt (DE...


1. A thermally vulcanizable pressure-sensitive adhesive comprising:a chemically precrosslinked, pressure-sensitively adhesive polybutadiene-polyurethane;
epoxy resin; and
ground sulfur.

US Pat. No. 11,110,139

APPLICATION OF ANTHOCYANIN EXTRACT IN PREPARING PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CARDIAC TOXICITY INDUCED BY ANTHRACYCLINES AND PHARMACEUTICAL COMPOSITION

Northwest Institute of Pl...


1. A method for preventing and treating cardiac toxicity induced by Anthracyclines, said method comprising administering a pharmaceutical composition comprising an effective dose of an anthocyanin extract to a subject in need thereof, and the anthocyanin extract is obtained from mature fruits of a zygophyllaceous nitraria plant and having a total anthocyanin content greater than 700 mg CGE/g and a total antioxidant capacity greater than 200 mg TE/g; wherein an anthocyanidin as a source of the anthocyanin extract comprises cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin.
US Pat. No. 11,112,713

TONER

CANON KABUSHIKI KAISHA, ...


1. A toner comprising:a toner particle containing a binder resin, wherein
the binder resin contains a crystalline resin,
an endothermic peak derived from the crystalline resin exists in a temperature-endothermic quantity curve obtained by differential scanning calorimetry of the toner, and
in viscoelasticity measurement of the toner with Tp being a peak temperature of the endothermic peak derived from the crystalline resin,
given G?(Tp?5, 0.01 Hz) as a storage modulus at a temperature of Tp?5° C. and a frequency of 0.01 Hz, G?(Tp?5, 10 Hz) as a storage modulus at a temperature of Tp?5° C. and a frequency of 10 Hz, and G?(Tp?30, 10 Hz) as a storage modulus at a temperature of Tp?30° C. and a frequency of 10 Hz, formulae below are satisfied:G?(Tp?30,10 Hz)/G?(Tp?5,0.01 Hz)?1.40
G?(Tp?5,10 Hz)/G?(Tp?5,0.01 Hz)?2.20.